Protective Effects of Melatonin on Neurogenesis Impairment in Neurological Disorders and Its Relevant Molecular Mechanisms

Joseph Wai-Hin Leung 1,2, Kwok-Kuen Cheung 3, Shirley Pui-Ching Ngai 3, Hector Wing-Hong Tsang 3,* and Benson Wui-Man Lau 3,*

1 Department of Biology, University of Ottawa, Ottawa, ON K1N 6N5, Canada; wleung2@uottawa.ca
2 Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada
3 Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong, China; alexkk.cheung@polyu.edu.hk (K.-K.C.); shirley.ngai@polyu.edu.hk (S.P.-C.N.)
* Correspondence: hector.tsang@polyu.edu.hk (H.W.-H.T.); benson.lau@polyu.edu.hk (B.W.-M.L.)

Received: 15 June 2020; Accepted: 1 August 2020; Published: 6 August 2020

Abstract: Neurogenesis is the process by which functional new neurons are generated from the neural stem cells (NSCs) or neural progenitor cells (NPCs). Increasing lines of evidence show that neurogenesis impairment is involved in different neurological illnesses, including mood disorders, neurogenerative diseases, and central nervous system (CNS) injuries. Since reversing neurogenesis impairment was found to improve neurological outcomes in the pathological conditions, it is speculated that modulating neurogenesis is a potential therapeutic strategy for neurological diseases. Among different modulators of neurogenesis, melatonin is a particularly interesting one. In traditional understanding, melatonin controls the circadian rhythm and sleep–wake cycle, although it is not directly involved in the proliferation and survival of neurons. In the last decade, it was reported that melatonin plays an important role in the regulation of neurogenesis, and thus it may be a potential treatment for neurogenesis-related disorders. The present review aims to summarize and discuss the recent findings regarding the protective effects of melatonin on the neurogenesis impairment in different neurological conditions. We also address the molecular mechanisms involved in the actions of melatonin in neurogenesis modulation.

Keywords: melatonin; neurogenesis; neural stem cell; neurogenesis impairment; neurological disorder; molecular mechanism; review

1. Introduction

Adult neurogenesis, namely, generation of new neurons, was discovered in the 1960s [1], while its involvement in behaviors and diseases were discovered in the last two decades since the discovery of the neurogenesis-promoting property of antidepressants [2]. Neurogenesis is implicated in different behaviors and brain functions [3]. For instance, neurogenesis in the subventricular zone (SVZ) is hypothesized to be responsible for the sexual and olfactory behavior, whereas neurogenesis taking place in the hippocampus is important for the learning and memory processes as well as pattern separation [4–7].

Melatonin is a hormone secreted by the pineal gland in the mammalian brain. Its first identified role is to regulate the circadian rhythm and the sleep–wake cycle [8]. Previously, it was hypothesized that melatonin is synthesized in the cytosol of cells; however, recent findings have shown that mitochondria is the original site of melatonin synthesis [9]. Melatonin synthesis has been found in mitochondria of different cells including oocytes, pinealocytes, endothelial cells, plant cells, and neurons [10]. Serotonin N-acetyltransferase (SNAT) is a melatonin synthetic enzyme, whereas N-acetyl-coenzyme A is an
irreplaceable substrate of SNAT. Since N-acetyl-coenzyme A is mainly synthesized in mitochondria instead of cytosol, this may further support the idea that melatonin is primary produced in mitochondria but not cytosol [10]. It was suggested that the main function of melatonin in mitochondria is to protect mitochondria from oxidative stress [11]. Melatonin activates two high affinity receptors—MT1 (Mel1a, MTNR1A) and MT2 (Mel1b, MTNR1B) [8]. MT1 and MT2 receptors are G protein-coupled receptors that are encoded by genes on human chromosome 4 and chromosome 11 [12]. Considering the functions of MT1 and MT2 receptors, apart from regulating the circadian rhythm, they are also responsible for different physiological functions, including reproduction, cardiovascular regulation, and immune function [13–16]. Melatonin is neuroprotective against the central nervous system (CNS) disorders, particularly the neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease [17,18]. In addition, it also protects the brain from ischemia injury. The neuroprotective effects of melatonin are mainly attributed to its antioxidant, anti-inflammatory, and anti-apoptotic properties, wherein the melatonin receptors are involved [19]. It has been claimed that the mitochondrial MT1 but not the plasma membrane MT1 is responsible for the protective effects of melatonin on the cerebral damage caused by ischemia, but this requires further confirmation [20].

Until recently, the neurogenic property of melatonin was undiscovered, with melatonin being found to play an important role in the regulation of neurogenesis [19]. Since neurogenesis impairment is linked to different CNS disorders, it is worth studying the effects of melatonin on neurogenesis impairment as well as the respective molecular mechanisms in neuropathological conditions. Here, we summarize and discuss the most updated findings in terms of this aspect.

2. Roles of Melatonin in Modulation of Neurogenesis

Melatonin has been shown to be involved in the modulation of neurogenesis in both in vivo and in vitro models [21] (Figure 1).

2.1. In Vitro Model

Melatonin promotes viability, proliferation, and neuronal differentiation of mouse embryonic cortical neural stem cells (NSCs) [22–24]. It enhances differentiation of embryonic NSCs into neurons through melatonin receptors (MT1/MT2) with the CBP/p300-mediated acetylation of histone H3 lysine 14 via extracellular signal-regulated kinase (ERK) signaling pathway [23]. Similar effects on the neural stem cell line were observed, where the expression of neuronal markers increased in the PC12 and C17.2 NSCs after treatment of melatonin via the activation of the PI3K/Akt pathway [25,26]. With the application of melatonin receptor antagonist luzindole, the effects of melatonin on the PC12 cells was abolished, leading to reduction in neurite outgrowth and decrease in the number of mature neurons [25]. In another cellular model, melatonin enhanced dopaminergic neuronal differentiation of embryonic day 14 (E14) rat midbrain NSCs, with the effect being potentially brought out by the increased production of brain-derived neurotropic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) in the NSCs [27]. Timing of melatonin treatment was found to be critical in the differentiation of NSCs. It was shown that melatonin promoted 1% fetal bovine serum (FBS)-induced neuronal differentiation during the proliferation period of E15.5 ganglionic eminence NSCs but it decreased neuronal differentiation of the NSCs during the differentiation period [28]. Melatonin also promoted the neuronal differentiation of amniotic fluid mesenchymal stem cells and mouse-induced pluripotent stem cells, in which ERK/CaMKII and PI3K/Akt signaling pathways were, respectively, involved [29,30]. In adult rat hippocampal organotypic culture experiments, melatonin was found to promote dendritogenesis by the activation of CaMKII, protein kinase C (PKC), and ERK1/2 with partial involvement of the melatonin receptors [31,32]. These results support the roles of melatonin on neurogenesis (Table 1).
Figure 1. Effects of melatonin and its receptor agonist/precursor on neurogenesis and nerve regeneration and the respective molecular mechanisms in different neuropathological conditions.
Table 1. Table showing the main findings regarding the effects of melatonin or its analog(s) on neurogenesis and the respective molecular mechanisms in the in vitro studies.

| Cells | Lowest Dosage Causing an Observable Effect | Main Findings | Molecular Mechanisms | References |
|-------|-------------------------------------------|---------------|----------------------|------------|
| Mouse cortical NSCs (E14) | 0.05 µM, 28-h treatment of melatonin | Increased NSC viability and proliferation | Not examined in the study | Ghareghani et al., 2017 [22] |
| Mouse cortical NSCs (E12.5) | 100 nM melatonin, 3-day treatment of melatonin | Promoted neuronal differentiation | Melatonin receptor MT1; ERK signaling pathway; CBP/p300-mediated acetylation of histone H3 lysine 14 | Li et al., 2017 [23] |
| Mouse cortical NSCs (E14) | $10^{-3}$ µM, 48-h treatment of melatonin or its analog IQM316 | Increased neuronal precursor marker expression (DCX) | Melatonin receptors (for the actions of melatonin but not the actions of IQM316) | Figueiro-Silva et al., 2018 [24] |
| Rat PC12 cells | 10 µM, 24-h treatment of melatonin | Enhanced cell proliferation Promoted neuronal differentiation | Melatonin receptors MT1/MT2; MEK/ERK and PI3K/AKT signaling pathways | Liu et al., 2016 [25] |
| Mouse C17.2 cells | 0.05 nM, 24-h treatment | Increased neuronal differentiation | Melatonin receptor MT1; Histone H3 acetylation | Sharma et al., 2008 [26] |
| Rat midbrain NSCs (E14) | 1 nM, 3-day treatment of melatonin | Increased NSC viability Promoted dopaminergic neuronal differentiation and decreased astrocyte production | Melatonin receptors MT1/MT2; BDNF and GDNF | Kong et al., 2008 [27] |
| Mouse NSCs (E15.5; from ganglionic eminence) | 5 µM, 4-day treatment of melatonin | Suppressed epidermal growth factor (EGF)-stimulated NSC proliferation Treatment during the proliferation period promoted 1% FBS-induced neural differentiation of NSCs Treatment during the differentiation period decreased neural differentiation of the NSCs | Not examined in the study | Moriya et al., 2007 [28] |
| Human amniotic fluid mesenchymal stem cells (16 to 20 week of pregnancy) | 0.1 µM, 2-day treatment of melatonin | Increased levels of dopaminergic neuron markers (TH and NURR1) Increased levels of neuronal protein marker (βIII-tubulin) Decreased levels of glial fibrillary acidic protein markers (GFAP) | ERK phosphorylation; CaMKII signaling pathway | Phonchai et al., 2019 [29] |
| Mouse-induced pluripotent stem cells | 1 µM, 7-day treatment of melatonin | Improved the differentiation of iPSCs into NSCs Promoted the differentiation of iPSC-derived NSCs into neurons | Melatonin receptors MT1/MT2; PI3K/AKT signaling pathway | Shu et al., 2016 [30] |
| 52–56-day-old adult rat hippocampal organotypic culture | $10^{-11}$ M, 6-h treatment of melatonin | Stimulated dendrite growth and dendrite formation Increased dendrite complexity | Not examined in the study | Dominguez-Alonso et al., 2012 [31] |
| Cells                                      | Lowest Dosage Causing an Observable Effect | Main Findings                        | Molecular Mechanisms                                      | References                        |
|-------------------------------------------|-------------------------------------------|--------------------------------------|-----------------------------------------------------------|-----------------------------------|
| 52–56-day-old adult rat hippocampal organotypic culture | 100 nM, 6-h treatment of melatonin        | Stimulated dendritogenesis            | Melatonin receptors MT1/MT2; CaMKII and PKC ERK1/2         | Domínguez-Alonso et al., 2015 [32] |
| Mouse adult hippocampal NSCs              | 10^{-8} μM, 48-h treatment of melatonin   | Increased neuronal differentiation     | Melatonin receptors MT1/MT2                                | Ramírez-Rodríguez et al., 2009 [33] |
| Mouse adult subventricular zone NSCs (8-week-old mice) | 0.001 μM, 7-day treatment of melatonin   | Increased NSC proliferation           | Melatonin receptor MT1                                     | Sotthibundhu et al., 2010 [34]   |
| Mouse adult subventricular zone NSCs (8-week-old mice) | 100 μM, 7-day treatment of melatonin      | Increased NSC proliferation           | Melatonin receptors MT1/MT2; ERK/MAPK signaling pathway    | Sotthibundhu et al., 2016 [35]   |
| Rat adult hippocampal NSCs (2-month-old rat) | 0.5 μM, 3-day treatment of melatonin      | Increased NSC proliferation           | Melatonin receptors MT1/MT2; phosphorylation of ERK1/2 and c-Raf | Tocharus et al., 2014 [36]       |
| Mouse adult spinal cord stem/progenitor cells (6-week-old mice) | 0.01 μM, 7-day treatment of melatonin | Promoted proliferation and maintenance of NSCs | Melatonin receptors MT1/MT2; PI3K/AKT signaling pathway | Yu et al., 2019 [37] |
2.2. In Vivo Models

Melatonin promotes adult neurogenesis in different models. From gain-of-function experiments, when mice were administered 8 mg/kg body weight (BW) melatonin daily for 7 or 14 days exogenously, the number of doublecortin-positive (DCX+) neuronal precursor cells in the dentate gyrus (DG) increased [38]. In addition, melatonin increased the structural plasticity of mossy fiber projection in the 8-week-old mice [39]. The roles of melatonin on adult neurogenesis were further confirmed by the loss-of-function pinealectomy experiments. In the pinealectomy experiments, the pineal gland, which is the primary production site of melatonin, was surgically removed from the animals. After rats were pinealectomized, the levels of melatonin decreased and neurogenesis in the hippocampus declined; however, the neurogenesis impairment was reversed by the melatonin treatment [40]. Male offspring of the mouse mothers, which were pinealectomized before pregnancy, also exhibited neurogenesis disruption, but the impairment could be alleviated by the melatonin treatment [41]. Apart from promoting neurogenesis, melatonin enhanced survival and dendritic maturation of the immature neurons in the hippocampus [33] (Table 2).

The neurogenic effects of melatonin were observed when the mice were treated at a dose as low as 2 mg/kg BW daily for 7 days [24]. This dosage of melatonin increased the number of BrdU+/NeuN+ cells in the DG and modulated the mitochondrial DNA copy number and oxidative phosphorylation proteins, including COX I, COX IV, ATP-5β, and NDUFB8 in the hippocampus [24]. In the aging animal studies, melatonin delayed the decline of the hippocampal neurogenesis in the 6- to 9-month-old aging mice [42]. Increased cell proliferation and higher number of calretinin+ neurons were observed in the DG in the aging mice which received the melatonin treatment [42,43]. Moreover, melatonin potentiated the running-wheel activity-induced cell survival and neurogenesis in the DG in 2–3-month-old mice [44] (Table 2).

Metlation receptors are involved in adult neurogenesis. When mice were subjected to 10 mg/kg luzindole daily for 14 days, DCX+ neuronal precursor cells and Ki-67+ proliferative cells in the subgranular zone (SGZ) reduced [45]. Ex vivo studies also showed that melatonin increased survival, proliferation, and differentiation of adult SVZ, hippocampal, and spinal cord NSCs through the melatonin receptors via the ERK/MAPK and PI3K/Akt signaling pathways [33–37] (Tables 1 and 2).
Table 2. Table showing the main findings regarding the effects of melatonin or its analog(s)/receptor antagonist on neurogenesis and the respective molecular mechanisms in the in vivo studies.

| Animals | Treatment Timeline and Dosage | Brain Regions | Main Findings | Behavioral Outcomes | Molecular Mechanisms | References |
|---------|-------------------------------|---------------|---------------|---------------------|----------------------|------------|
| 3-month-old male C57BL/6j mice | 2 mg/kg BW melatonin or its analog IQM316, administered daily for 7 or 28 days | Dentate gyrus | Melatonin and IQM316 increased BrdU+/NeuN+ cells | IQM316 improved memory | Modulation of mitochondrial DNA copy number and oxidative phosphorylation proteins (COX I, COX IV, ATP-5β, and NDUFB8) | Figueiro-Silva et al., 2018 [24] |
| Adult C57BL/6 mice | 8 mg/kg BW melatonin, intraperitoneally injected daily for 14 days | Dentate gyrus | Increased number of DCX+ neuronal precursor cells | Not examined in the study | Not examined in the study | Ramirez-Rodriguez et al., 2011 [36] |
| 8-week-old male BALB/c mice | ≈8 mg/kg BW melatonin, via drinking water for 1 or 6 months | Dentate gyrus | Modulated structural plasticity of mossy fiber projection | N/A | Not examined in the study | Ramirez-Rodriguez et al., 2018 [39] |
| 1-month-old male SD rats | Rats were pinealectomized and treated with 6mg/L melatonin in drinking water starting from 1 week after surgery for 2, 4, 6, 8, 10, or 17 months | Dentate gyrus | Promoted neurogenesis in the pinealectomized rats | Not examined in the study | Not examined in the study | Rennie et al., 2009 [40] |
| Pregnant rats’ offspring (PND35-77) | 8-week-old female pregnant rats subjected to pinealectomy and allowed to mate with adult males 30 days after surgery | Subgranular zone | Male offspring with no melatonin treatment showed lower number of Ki67+ cells when compared to the offspring which received melatonin treatment during gestation and lactation period | Male offspring showed deficits in righting reflex, free-fall righting and walking | Not examined in the study | Motta-Teixeira et al., 2018 [41] |
| Female 8-week-old C57BL/6 mice | 8 mg/kg BW melatonin, orally administered daily for 7 or 14 days | Dentate gyrus | Increased survival of new-born neurons and increased the number of intermediate neuronal progenitor cells and immature post-mitotic neurons | Reduced antidepressant-like behavior (Porsolt forced swim test) | Not examined in the study | Ramirez-Rodriguez et al., 2009 [33] |
| Adult male BALB/c mice | 8 mg/kg BW melatonin, orally administered daily for 3, 6, 9, or 12 months | Dentate gyrus | Increased proliferation and survival of new cells and increased number of DCX+ cells | Not examined in the study | Not examined in the study | Ramirez-Rodriguez et al., 2012 [42] |
| 8-week-old male BALB/c mice | 8 mg/kg BW melatonin, orally administered every 3 days for 1, 3, or 6 months | Dentate gyrus | Increased number of calretinin+ neurons | Not examined in the study | Not examined in the study | Ramirez-Rodriguez, et al., 2014 [43] |
| 2–3-month-old male C3H/HeN mice | 0.02 mg/mL melatonin in drinking water for 12 days | Dentate gyrus | Potentiated running-wheel activity-induced cell survival and neurogenesis | Not examined in the study | Not examined in the study | Liu, et al., 2013 [44] |
| Female C57BL/6 mice | 10 mg/kg BW luzindole, administered daily for 14 days | Subgranular zone | Decreased DCX+ neuronal precursor cells and decreased Ki67+ proliferative-cells, increased GFAP+/ Sox2+ neural stem cells | No effect on the hopeless behavior | Melatonin receptors MT1/MT2 | Ortiz-López et al., 2016 [45] |
3. Melatonin and Depression

According to the neurogenesis hypothesis of depression, the disturbance of mood and emotion is linked to the impairment of neurogenesis, and restoration of neurogenesis would be a critical factor for the remission from the disease [2,46–48]. If neurogenesis is suppressed, the beneficial effects of antidepressants would be abolished, which may indicate that reversing neurogenesis deficits is a potential therapeutic target of depression [49]. The protective effects of melatonin on depression has been well documented. Depression-like behavior in male BALB/c mice was reduced when they were treated with 5 and 10 mg/kg BW melatonin daily for 7 days [50]. Melatonin reduced the immobility behavior of the mice in the forced swim test [50], and coincidently, neurogenesis and dendrite maturation in those mice were promoted [50]. Corticosterone (CORT) contributes to the onset of depression-like behavior in rodents. The CORT depression model is a well-established model for studying depression. It was shown that 3-week daily treatment of 10 mg/kg BW melatonin prevented CORT-induced reduction in cell proliferation in the DG and reduced depression- and anxiety-like behavior of the mice in the forced swim test, open field test, and novelty suppressed feeding test [51]. The anti-depressive and neurogenetic effects of melatonin was potentially brought about by the inhibition of the acid sphingomyelinase/ceramide system as well as the decrease in vesicular monoamine transporter 2 (VMAT2) levels and increase in the monoamine oxidase A MAO-A levels in the hippocampus [52,53]. Using combination treatment of melatonin and citalopram (MLT/CITAL), 14-day daily treatment of 2.57 mg/kg BW MLTCITAL promoted neurogenesis and reduced depression-like behavior in adult mice [54] (Table 3).

Agomelatine is a mixed MT1/MT2 melatonin receptor agonist and 5HT2C serotonin receptor antagonist. Agomelatine was able to reverse the decline of neurogenesis regulators including p-CREB, mGlu2/3, and mGlu5 receptor levels in the hippocampus, and prevented the neurogenesis impairment and depression- and anxiety-like behaviors in the adult male offspring of mouse mothers who were subjected to restraint stress during pregnancy [55]. In addition, agomelatine also protected against light stress-induced neurogenesis deficits by upregulating BDNF levels and inhibiting the apoptotic signaling pathway [56]. It was also reported that agomelatine increased neurogenesis via the 5HT2C receptor with the activation ERK1/2, protein kinase B, and GSK3β [57,58] (Table 3).
Table 3. Table showing the main findings regarding the effects of melatonin and its receptor agonist on neurogenesis in depression and the respective molecular mechanisms in the in vivo studies.

| Animals | Treatment Timeline and Dosage | Brain Regions | Main Findings | Behavioral Outcomes | Molecular Mechanisms | References |
|---------|-------------------------------|---------------|---------------|---------------------|----------------------|------------|
| Male BALB/c mice | 0.5, 1.0, 2.5, 5.0, and 10 mg/kg BW melatonin, intraperitoneally injected once daily for 14 days | Dentate gyrus | Increased number of DCX+ neuronal precursor cells | Decreased depression-like behavior (forced swim test) | Not examined in the study | Ramírez-Rodriguez et al., 2020 [50] |
| 7-8-week-old male CD1 mice subjected to corticosterone for 7 weeks | 10 mg/kg BW melatonin, intraperitoneally injected for 3 weeks | Dentate gyrus | Prevented corticosterone-induced reduction in cell proliferation | Reduced depression- and anxiety-like behavior (forced swim test, open field test, and novelty suppressed feeding test) | Not examined in the study | Crupi et al., 2010 [51] |
| 6-week-old mice with C57BL/6H background subjected to corticosterone via drinking water for 14 days | 10 mg/kg BW melatonin, intraperitoneally injected twice daily for 12 days | Hippocampus | Increased neurogenesis | Improvement in depression- and anxiety-like behavior (dark-light box and novelty suppressed feeding tests) | Acid sphingomyelinase/ceramide system | Hoehn et al., 2016 [52] |
| 11-week-old male Wistar rat subjected to chronic unpredictable mild stress for 28 days | 10 mg/kg BW melatonin, intraperitoneally injected daily for 4 weeks | Hippocampus | Effects on neurogenesis were not examined in the study | Decreased depression-like behavior (forced swim test) | Decreased VMAT2 expression and increased MAO-A expression | Stefanovic et al., 2016 [53] |
| 8-week-old male BALB/c mice | 1.28, 5.75, 9.13, and 10.26 mg/kg BW combination of melatonin plus citalopram, intraperitoneally injected once daily for 14 days | Dentate gyrus | Increased cell proliferation and survival | Decreased depression-like behavior (forced swim test) | Not examined in the study | Ramírez-Rodriguez et al., 2014 [54] |
| Female SD rats subjected to prenatal restraint stress (starting from E11 until giving birth) (Bright light (650 Lux)) | 2–3-month-old male offspring were treated with 10–50 mg/kg BW agomelatine, intraperitoneally injected once daily for 3 or 6 weeks | Dentate gyrus | Increased survival of the proliferative cells | Reduced depression- and anxiety-like behavior (forced swim test and elevated plus maze) | Increased p-CREB, mGlu2/3, and mGlu5 receptor levels | Morley-Fletcher et al., 2011 [55] |
| 12-week-old female Wistar rats subjected to light stress for 1 week | 10 and 40 mg/kg BW agomelatine, intraperitoneally injected once daily for 15 days | Hippocampus | Increased neurogenesis | Not examined in the study | BDNF; apoptotic signaling pathway (Bcl-2 and caspase 3) | Yue et al., 2016 [56] |
| 8-week-old male SD rats | 40 mg/kg BW agomelatine, intraperitoneally injected once daily for 14 days | Dentate gyrus | Increased number of Ki 67+ cells | No effect on cell proliferation in rats which were implanted with corticosterone pellet with addition of corticosterone injection | Not examined in the study | 5HT2C receptor | AlAhmed et al., 2010 [57] |
| 7-week-old male Wistar rats | 40 mg/kg BW agomelatine, intraperitoneally injected once daily for 8, 15, or 21 days | Hippocampus | Increased neuronal maturation, cell survival, and cell proliferation | Not examined in the study | BDNF; ERK1/2, AKT, and GSK3β signaling pathways | Soumier et al., 2009 [58] |
4. Melatonin, Aging, and Neurodegenerative Diseases

Melatonin can decelerate the progress of aging. Melatonin improved spatial memory deficits in the mouse model of d-galactose (d-gal)-induced aging and restored the reduction of Ki67+ proliferative cells and DCX+ neuronal precursor cells caused by the d-gal in the DG [59]. Senescence-accelerated (SAMP8) mice is another mouse model of aging, which presented age-related defects such as cognitive disability and motor dysfunction [60]. When the SAMP8 mice were given melatonin treatment from the ages of 1 month to 10 months old, the levels of acetylated p53, NF-κB, and amyloid β (Aβ) in the brain decreased and the levels of α-secretase and Bcl-2XL increased, which suggested that melatonin exerted anti-aging effects by modulating the pro-survival and pro-death signals in the brain [61]. However, the study did not examine the relationship between the survival/death signals and neurogenesis (Table 4).

Table 4. Table showing the main findings regarding the effects of melatonin on neurogenesis in aging and neurodegenerative diseases and the respective molecular mechanisms in the in vivo studies.

| Animals | Treatment Timeline and Dosage | Brain Regions | Main Findings | Behavioral Outcomes | Molecular Mechanisms | References |
|---------|-------------------------------|---------------|---------------|---------------------|----------------------|------------|
| Male C57BL6 mice subjected to d-galactose (d-gal) for 7 weeks (animal model of aging) | 6 mg/mL melatonin in drinking water for 3 weeks | Dentate gyrus | Restored d-gal-induced reduction of Ki67+ proliferative cells and DCX+ neuronal precursor cells | Improved spatial memory (Morris water maze) | Increased Ser133-phosphorylated cyclic AMP response element binding protein; decreased d-gal-induced lipid peroxidation | Yoo et al., 2012 [62] |
| 10-month-old senescence-accelerated mice (SAMP8) (animal model of aging) | <10 mg/kg BW melatonin, via drinking water (from 1 month old to 10 months old) | Brain | Effects on neurogenesis were not examined in the study | Not examined in the study | Decreased acetylated p53 and NF-κB; increased α-secretase; decreased amyloid β (Aβ); increased Bcl-2XL levels | Gutierrez-Cuesta et al., 2008 [63] |
| 8-week-old male C57BL6 mice treated with methamphetamine (METH) (animal model of Alzheimer’s disease) | 5 mg/kg BW melatonin, subcutaneously injected for 7 days | Hippocampus | Increased expressions of Nestin, DCX, and Beta-III tubulin | Not examined in the study | Attenuated the METH-induced change in MAPK signaling activity, NMDA receptor subunits (NR2A and NR2B) and CaMKII | Singhakumar et al., 2015 [64] |
| 8-week-old male C57BL6 mice given 0.2% cuprizone in the chow diets (animal model of demyelinating disease) | 6 mg/mL melatonin in drinking water for 6 weeks | Dentate gyrus | Ameliorated cuprizone-induced reduction of DCX+ neuronal precursor cells and Ki-67 proliferating cells | Not examined in the study | Increased glucose utilization (GLUT3); increased pCREB; increased BDNF | Kim et al., 2019 [65] |
| APP/PS1 mice (animal model of Alzheimer’s disease) | 0.1 mg/kg BW melatonin, via drinking water (starting from 4 to 8 months of age) | Cortex and the hippocampus | Effects on neurogenesis were not examined in the study | Reduced spatial learning and memory deficits | Increased levels of mitochondrial biogenesis factors; enhanced mitochondrial DNA copy number; reduced Aβ | Song et al., 2018 [66] |

Parkinson’s disease (PD) is a neurodegenerative disease that is linked to motor and learning dysfunction [67]. Melatonin attenuates neurogenesis impairment in different PD animal models. For instance, 7-day treatment of 5 mg/kg BW melatonin reversed the decline of Nestin, DCX, and Beta-III tubulin expression in the hippocampus in the methamphetamine (METH)-induced PD mice by modulating the MAPK signaling activity, N-methyl-d-aspartate (NMDA) receptor subunits (NR2A and NR2B), as well as CaMKII levels [62]. Transplantation of 25 μM melatonin-pretreated SVZ NSCs to the hippocampus and striatum also improved neuronal restoration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice [63]. Moreover, combination treatment of melatonin and NSC transplantation rescued tyrosine hydroxylase (TH) neurons and attenuated the behavioral deficits in the 6-hydroxydopamine (6-OHDA)-induced PD mouse model [64].
In the in vitro experiments, melatonin was shown to prevent the METH-induced inhibition of proliferation of NSCs by modulating the tumor suppressor p53 and cycle inhibitor p21CIP as well as regulating the CaMKII, NR2A, and NR2B [68] (Tables 4 and 5).

**Table 5.** Table showing the main findings regarding the effects of melatonin on neurogenesis in neurodegenerative disease(s) and the respective molecular mechanisms in the in vitro studies.

| Cells | Lowest Dosage Causing an Observable Effect | Main Findings | Molecular Mechanisms | References |
|-------|------------------------------------------|---------------|----------------------|------------|
| Rat adult hippocampal NSCs treated with 500 µM METH for 2 days (Parkinson’s disease) | 1 µM, 2-day treatment of melatonin (starting from 30 min prior to the METH treatment) | Reversed METH-induced inhibition of NSC proliferation | Reversed METH-induced changes in tumor suppressor p53, cycle inhibitor p21CIP, NMDA receptor subunits (NR2A and NR2B), and CaMKII | Ekthuswapiemee et al., 2015 [68] |

Apart from Parkinson’s disease, melatonin was found to rescue neurogenesis impairment in demyelinating disease. Melatonin prevented reduction of DCX+ neuronal precursor cells and Ki-67 proliferating cells in the DG through the phosphorylation of CREB and upregulation of glucose transporter 3 (GLUT3) and BDNF levels [65]. Melatonin is also neuroprotective against Alzheimer’s disease (AD) [63,66]. Melatonin alleviated the AD-induced spatial learning and memory deficits by reducing the Aβ levels and modulating the mitochondrial biogenesis factors and DNA copy number in the brain [66]. However, the role of melatonin in the regulation of neurogenesis in AD has not yet been fully studied (Table 4).

5. Melatonin and Central Nervous System (CNS) Injury

Melatonin was shown to confer neuroprotective effects in stroke with yet elusive mechanisms. It was hypothesized that melatonin protected against stroke due to its anti-inflammatory and anti-oxidant properties. Recent studies reported that melatonin may also promote stroke recovery by regulating post-stroke neurogenesis. When mice were subjected to the middle cerebral ischemic/reperfusion injury (CI/R), it was found that melatonin treatment could reduce the post-stroke free radical production, increasing the number of the DCX+ neuroblasts and Ki67+ proliferative cells in the peri-infarcted area (e.g., the cortex) [69]. For those Ki-67+ cells, they were not only DCX+, but the majority of them were also Nestin+ and NG2+ [69]. Nestin and NG2 are the markers of NSC and oligodendrocyte precursors, respectively. The findings were further supported by another study that showed that melatonin increased PCNA+ and NG2+ oligodendrocyte progenitor cells in the SVZ and white matter in the rat after the focal cerebral ischemia with the downregulation of inflammatory factors, including TLR4, NF-κB, and IL-1β [70] (Table 6).

On neurological functions, melatonin improved motor and coordination of post-stroke mice in the grip strength and rotarod tests [71]. Melatonin also attenuated the hyperactivity and anxiety behavior of the mice in the open field test after stroke [71]. It was found that the improvements were associated with the promotion of endogenous neurogenesis in the lateral ventricle, striatum, and cortex after melatonin treatment [71]. Nevertheless, in the global forebrain ischemia experiment, which used 3- to 4-month-old Mongolian gerbils as the animal model, it was found that chronic but not acute melatonin treatment could improve the post-stroke behavioral outcome [72], and instead of enhancing the post-stroke neurogenesis, both chronic and acute melatonin suppressed the increased neurogenesis after stroke [72] (Table 6).

Melatonin facilitated the efficiency of post-stroke mesenchymal stem cell (MSC) transplantation therapy. Melatonin enhanced the survival of MSCs through the ERK1/2 signaling pathway via the melatonin receptors [73]. When the MSCs were pretreated with 5 mM melatonin for 24 h and transplanted to the ipsilateral striatum in the rats after stroke, the rats exhibited improved behavioral outcomes with an increase in the levels of neurogenesis and angiogenesis. The effects may be brought by the upregulation of vascular endothelial growth factor (VEGF) after the transplantation therapy [73] (Table 6).
Table 6. Table showing the main findings regarding the effects of melatonin on CNS injuries and the respective molecular mechanisms in the in vivo studies.

| Animals | Treatment Timeline and Dosage | Brain Regions | Main Findings | Behavioral Outcomes | Molecular Mechanisms | References |
|---------|-----------------------------|---------------|---------------|---------------------|----------------------|------------|
| Male ICR mice subjected to middle cerebral ischemia/reperfusion injury (CIR) | 5 or 10 mg/kg melatonin, intraperitoneally injected once daily (starting from 2 h after CIR) or 10 mg/kg melatonin, 30 min before CIR, and then intraperitoneally injected daily | Cortex | Melatonin increased DCX+ and kit+7+ cells | Improved survival; preserved blood–brain barrier (BBB) integrity; reduced free radical production; decreased gp91phox cell infiltration | Melatonin receptors | Chern et al., 2012 [69] |
| Male SD rats subjected to middle cerebral artery occlusion (MCAO) (focal cerebral ischemia) | 5 mg/kg BW melatonin, intraperitoneally injected 30 min before and after ischemia/reperfusion (IR) | Subventricular zone and white matter areas | Melatonin increased (PCNA+N(G2) + oligodendrocyte progenitor cells after MCAO | Reduction in infarct volume and white matter damage | TLRA, NF-κB, and IL-1β | Zhao et al., 2019 [70] |
| Adult male C57Bl6j mice subjected to mild focal cerebral ischemia | 4 mg/kg BW melatonin, single i.p. bolus injection at 24 h after reperfusion, plus 0.025 mg/mL melatonin in drinking water (starting from 24 h after reperfusion and continued for 29 days) | Striatum, cortex, and lateral ventricle | Melatonin increased neuronal survival and enhanced neurogenesis | Improvement in motor and coordination deficits (grip strength and rotaord tests) | Attenuated hyperactivity and anxiety (open field test) | Not examined in the study Kilic et al., 2008 [71] |
| 3- to 4-month-old Mongolian gerbils subjected to global forebrain ischemia | 10 mg/kg BW melatonin, intraperitoneally injected 30 min prior ischemia followed by injections at 1, 2, and 6 h after occlusion (acute treatment) or 0.6mg/kg BW melatonin daily, via drinking water (starting from 2 weeks before ischemia until the end of experiment) (chronic treatment) | Dentate gyrus and CA1 hippocampus | DCX+ neuronal precursor cells increased after ischemia, and acute and chronic melatonin treatment reduced the number of DCX+ cells | Chronic but not acute melatonin attenuated ischemia-induced hyperactivity 3 days after occlusion (open field test) | Not examined in the study Rennie et al., 2008 [72] |
| Adult male SD rats subjected to MCAO | Mesenchymal stem cells (MSCs) were pretreated with 5 mM melatonin for 24 h and were transplanted into the striatum of the ipsilateral hemisphere | Subventricular zone, striatum, and cortex | Melatonin increased angiogenesis and neurogenesis after MCAO | Improved behavioral outcomes (neurological scores, rotaord test, and elevated body swing test) | Increased VEGF; improved MSC survival via melatonin receptors | Tang et al., 2014 [73] |
| 8-week-old SD rats subjected to spinal cord injury (SCI) | 10 mg/kg BW melatonin, subcutaneously injected twice daily (starting from 1 day after SCI until the end of experiment) or melatonin treatment plus treadmill exercise | Peri-lesion site | Combination treatment increased numbers of BrdU+ proliferative cells and Nestin+ NSCs after SCI | Combination treatment improved hindlimb function | Not examined in the study Lee et al., 2014 [74] |
| Postnatal day (PND1) mice subjected to hypoxia (5% oxygen and 95% nitrogen) for 2 h | 10 mg/kg BW melatonin, intraperitoneally injected 1 h before hypoxia and then daily for 3 days | Hippocampus | Melatonin increased BrdU+ proliferating cells and DCX+ neuronal precursor cells after hypoxia Reduced cell death | Attenuated neurobehavioral deficits (sensorimotor performance, locomotor functions, and hyperactivity) | Improved learning and memory performance (Morris water test) | Wang et al., 2013 [75] |
| PND7 SD rats subjected to kainic acid (KA)-induced neurodevelopmental injury | 10 mg/kg BW melatonin, intraperitoneally injected daily for 6 days (starting at 4 h after KA administration) | Hippocampus | Melatonin prevented hippocampal neuronal loss but had no effect on neurogenesis | Not examined in the study | Not examined in the study Csernansky et al., 2006 [76] |
Apart from stroke, melatonin protects against spinal cord injury (SCI). Melatonin treatment increased dendritic spine density in the peri-lesion site in the rats after SCI [74]. When the SCI rats received combined treatment of melatonin and treadmill exercise training, the hindlimb function in the injured animals were significantly improved in the Basso, Beattie, and Bresnahan (BBB) locomotor recovery scale. Meanwhile, the combination treatment also increased the number of BrdU⁺ proliferative cells and NSCs in the peri-lesion area [74] (Table 6).

In addition to SCI, melatonin was found to be protective on early-life CNS injuries such as perinatal hypoxia. Melatonin prevented microglial activation and downregulated the inflammatory mediators (e.g., TNFα, IL-1β, and nitric oxide) in the PND1 mice, which were subjected to the hypoxia at 5% oxygen and 95% nitrogen for 2 h [75]. Moreover, melatonin promoted neurogenesis and improved long-term deficits of the hypoxia-injured mice. It also attenuated the sensorimotor and locomotor function impairments, learning and memory deficits, and hyperactivity behavior of the mice 30 days after hypoxia [75]. In the in vitro study, when E12.5 mouse cortical NSCs were treated with 100 nM melatonin before being subjected to 12-h 95% N₂ and 5% CO₂ hypoxia incubation, the proliferation and neuronal differentiation of NSCs were restored by the phosphorylation of ERK1/2 via the MT1 receptor [77] (Tables 6 and 7).

**Table 7.** Table showing the main findings regarding the effects of melatonin on neurogenesis in CNS injuries and the respective molecular mechanisms in the in vitro studies.

| Cells                                      | Lowest Dosage Causing an Observable Effect | Main Findings                                                                 | Molecular Mechanisms          | References         |
|--------------------------------------------|-------------------------------------------|--------------------------------------------------------------------------------|-------------------------------|--------------------|
| Mouse cortical NSCs (E12.5) subjected to hypoxia (95% N₂ and 5% CO₂) for 12 h | 100 nM melatonin, treated before hypoxia | Melatonin increased proliferation and neuronal differentiation of NSCs during hypoxia | MT1 receptor; phosphorylation of ERK1/2 | Fu et al., 2011 [77] |
| Rat NSCs (E13.5) transfected with miR-363 (vitamin A deficiency (VAD)-induced congenital spinal deformities model) | 1 ng/mL melatonin, treated for 24 h | Melatonin promoted proliferation, increased Nestin expression, and promoted neuronal differentiation in miR-363-transfected NSCs | Notch signaling               | Li et al., 2019 [78] |

miR-363 was upregulated in the vitamin A deficiency (VAD)-induced congenital spinal deformities model. It was found that melatonin could promote proliferation, increased Nestin expression, and enhanced neuronal differentiation of the miR-363-transfected E13.5 rat NSCs [78]. In another CNS injury model, rats were exposed to kainic acid by intracerebroventricular administration on PND7 for the induction of neurodevelopmental injury. Melatonin protected against kainic acid-induced neurodevelopmental injury by preventing hippocampal neuronal loss without altering neurogenesis [76] (Tables 6 and 7).

6. Melatonin and Sleep Deprivation

Sleep deprivation (SD) suppresses neurogenesis in the adult hippocampus [79]. SD also causes adverse effects on neurological behavioral outcomes [80]. It is speculated that hippocampal neurogenesis impairment is responsible for SD-induced behavioral deficits (Table 8).

However, melatonin could rescue the neurogenesis deficits in SD. When mice were subjected to SD for 96 h, a 4-day daily treatment of 10 mg/kg BW melatonin restored the SD-induced reduction in the number of Sox2⁺/BrdU⁺ NSCs in the DG by increasing the levels of methyl-CpG-binding protein 2 (MECP2) and decreasing the levels of Sirtuin 1 (SIRT1) [81]. In addition, melatonin could also increase the number of BrdU⁻/Nestin⁻ NSCs in the SGZ in SD mice by upregulating the Bcl-2 and Bcl-XL levels [82]. N-acetylserotonin (NAS) is an immediate precursor of melatonin. It was found that NAS could prevent the suppression of NSC proliferation induced by SD via the TrkB signaling pathway [83] (Table 8).
Table 8. Table showing the main findings regarding the effects of melatonin or its precursor on neurogenesis in sleep deprivation and “jet lag” and the respective molecular mechanisms in the in vivo studies.

| Animals | Treatment Timeline and Dosage | Brain Regions | Main Findings | Behavioral Outcomes | Molecular Mechanisms | References |
|---------|-------------------------------|---------------|---------------|---------------------|-----------------------|------------|
| PND 60 male BALB/c mice subjected to sleep deprivation (SD) for 96 h | 10 mg/kg BW melatonin, intraperitoneally injected daily for 4 days | Dentate gyrus | Restored the reduction in the number of Sox2+/BrdU+ NSCs | Not examined in the study | Increased MECP2; reduced SIRT1; increased let-7b, mir-132, and mir-124 | Hinojosa-Godinez et al., 2019 [81] |
| Adult male BALB/c mice subjected to SD for 96 h | 10 mg/kg BW melatonin, via drinking water (for 14 days before SD, and during SD until the end of the experiment) | Subgranular zone | Increased BrdU/Nestin+ NSCs | Not examined in the study | Increased Bcl-2 and Bcl-xL | López-Armas et al., 2016 [82] |
| 2-to 3-month-old C57BL/6 mice or C3H (+/+) mice subjected to SD for 96 h | 20 mg/kg BW N-acetylserotonin (NAS) (immediate precursor of melatonin), intraperitoneally injected every 12 h during SD | Dentate gyrus | Protected SD-induced suppression of NSC proliferation | Not examined in the study | TrkB and its downstream signaling pathway | Sompol et al., 2011 [83] |
| 6-week-old female C57Bl/6N mice subjected to 3 weeks of photoperiod alterations simulating “jet lag” | 10 mg/kg BW melatonin, intraperitoneally injected daily until the end of experiment (2.5 weeks or 4 weeks) | Dentate gyrus | Prevented the reduction of cell proliferation | Prevented cognitive deficits | Not examined in the study | Iggena et al., 2017 [84] |
Apart from SD, melatonin protected against the photoperiod alterations simulating “jet lag” [84]. Melatonin prevented the reduction of cell proliferation and attenuated the cognitive deficits caused by “jet lag” [84]. However, the underlying mechanism remains unclear (Table 8).

7. Melatonin, Inflammation, and Oxidative Stress

Due to its antioxidant properties, melatonin helps reduce inflammation and oxidative stress. Melatonin can scavenge free radicals, reactive oxygen species (ROS), and reactive nitrogen species (RNS) directly [85]. It can also scavenge hydrogen peroxide (H_2O_2) and neutralize the toxic hydroxyl radicals [86]. Inducible NO synthase (iNOS) generates nitric oxide (NO), which is a free radical [87]. Excessive amount of NO generated by iNOS can cause cytotoxic changes in cells [87]. Melatonin is able to inhibit iNOS and decrease NO levels [88,89]. It was also reported that, by regulating NOS expression, melatonin protected the brain in terms of pathological conditions such as ischemic brain injury [90]. In addition, pretreatment of melatonin was found to reduce nitric oxide (NO) levels and prevent E14 cortical NSCs from apoptosis after lipopolysaccharide (LPS) exposure [91] (Table 9).

Melatonin protects NSCs against inflammation and oxidative stress, not only through the regulation of NO levels. The study also showed that melatonin protected NSCs from LPS-induced cell death by activating the PI3K/Akt/Nrf2 signaling pathway [91] (Table 9).

H_2O_2 induces oxidative stress to iPSC-derived NSCs. H_2O_2 was shown to decrease proliferation and viability of iPSC-derived NSCs and reduced their mitochondrial membrane potential [92]. Melatonin, however, could reverse all the adverse effects induced by H_2O_2 by the activation of the PI3K/Akt signaling pathway via the melatonin receptors [92]. IL-18 is a cytokine that is detrimental to the NSCs. Melatonin, moreover, could promote the production of BDNF and GDNF in the IL-18-stimulated NSCs and suppressed the IL18-induced inhibition of proliferation, neurosphere formation, and neuronal differentiation of the NSCs [93] (Table 9).

Table 9. Table showing the main findings regarding the effects of melatonin on neurogenesis in inflammation and oxidative stress and the respective molecular mechanisms in the in vitro studies.

| Cells | Lowest Dosage Causing an Observable Effect | Main Findings | Molecular Mechanisms | References |
|-------|------------------------------------------|---------------|----------------------|------------|
| Mice cortical NSCs (E14) exposed to 100 ng/mL or 1 μg/mL LPS | 100nM melatonin, treated before and 1 day after LPS exposure | Suppressed LPS-induced inflammation and nitric oxide (NO) production; Prevented LPS-induced cell death and apoptosis; Increased SOX2 expression | PI3K/Akt/Nrf2 signaling | Song et al., 2015 [91] |
| iPSC-derived NSCs pretreated with 500 μM H_2O_2 | 1 μM melatonin, treated for 3 days | Increased proliferation of iPSC-derived NSCs; Stabilized the mitochondrial membrane potential; Prevented H_2O_2-induced apoptosis | Melatonin receptors; PI3K/AKT signaling pathway | Shu et al., 2018 [92] |
| Rat NSCs (E13.5) treated with IL-18 | 10 ng/mL melatonin, treated for 3 days | Reduced IL-18-induced inhibition of proliferation, neurosphere formation, and neuronal differentiation | BDNF and GDNF | Li et al., 2017 [93] |

8. Melatonin and Neurogenesis Impairment Caused by Environmental Factors

Neurogenesis impairment can be caused by environmental factors, which leads to different neurological deficits. Scopolamine is a prescription drug used for the prevention of nausea and vomiting. When mice were treated with scopolamine for 2 weeks, it was found that the number of DCX+ neuronal precursor cells and Ki67+ proliferative cells decreased in the DG, wherein the mice exhibited spatial learning and short-term memory impairments in the Morris water maze test and passive avoidance test [94]. However, when the mice were treated with melatonin, neurogenesis was restored and behavioral deficits were attenuated [94]. Apart from scopolamine, other drugs and chemicals such as 5-fluorouracil (5-FU), valproic acid (VPA), and methotrexate (MTX) also caused hippocampal neurogenesis impairment in rats, but the impairments could be reversed by melatonin treatment [95–97] (Table 10).
Table 10. Table showing the main findings regarding the effects of melatonin or its precursor and metabolite on neurogenesis impairment caused by environmental factors and the respective molecular mechanisms in the in vivo studies.

| Animals | Treatment Timeline and Dosage | Brain Regions | Main Findings | Behavioral Outcomes | Molecular Mechanisms | References |
|---------|--------------------------------|---------------|---------------|---------------------|----------------------|------------|
| Male 8-week-old ICR mice subjected to scopolamine (Sco) for 2 or 4 weeks | 10 mg/kg melatonin, intraperitoneally injected for 2 or 4 weeks | Dentate gyrus | Restored the decrease in DCX+ neuronal precursor cells and Ki67+ proliferative cells | Improved spatial learning and short-term memory impairment (Morris water maze test and passive avoidance test) | Not examined in the study | Chen et al., 2018 [94] |
| Male 8-week-old ICR mice subjected to scopolamine (Sco) for 2 or 4 weeks | 8 mg/kg BW melatonin, intraperitoneally injected for 21 or 42 days | Subgranular zone | Ameliorated the reduction in neurogenesis | Reversed spatial memory deficits | Not examined in the study | Sirichoat et al., 2020 [95] |
| 8-week-old male ICR mice exposed to dexamethasone (DEX) | 50 mg/kg BW melatonin, intraperitoneally injected for 30 min before DEX exposure | Dentate gyrus | Restored the DEX-induced reduction in DCX and BrdU expression | Reversed DEX-induced depressive-like behavior (forced swim test) | Prevented DEX-induced reduction in glucocorticoid receptor (GR), ERK1/2 | Ruksee et al., 2014 [98] |
| PND8 male Wistar rats exposed to morphine sulfate | 1 mg/kg BW melatonin or 20 mg/kg BW N-acetylserotonin (NAS), intraperitoneally injected 30 min before ketamine exposure | Hippocampus | Effects on neurogenesis were not examined in the study | Attenuated the ketamine-induced immobility in the forced swim test (FST) | MEK-ERK and PI3K-AKT pathways; BDNF | Choudhury et al., 2016 [100] |
| Zebrafish exposed to fenvalerate (FEN) 5 h after fertilization | 10^9 mol/L melatonin, treated 3 h prior to FEN exposure for 120 hpf | Whole zebrafish | Reduced oxidative stress and apoptotic responses induced by FEN | Ameliorated FEN-induced abnormality in swimming behavior | Reduced malondialdehyde levels and activities of Cu/Zn superoxide dismutase (Cu/Zn SOD), catalase, and glutathione peroxidase; suppressed pro-apoptotic genes (Bax, Fas, caspase 8, caspase 9, and caspase 3); increased expression of anti-apoptotic gene (Bcl-2) | Han et al., 2017 [101] |
### Table 10. Cont.

| Animals | Treatment Timeline and Dosage | Brain Regions | Main Findings | Behavioral Outcomes | Molecular Mechanisms | References |
|---------|-------------------------------|---------------|---------------|---------------------|----------------------|------------|
| Male offspring of female rats which were exposed to a single dose of 1 Gy 60 Co gamma rays (Gy) during pregnancy | 4 mg/kg BW melatonin, via drinking water (PND14–20), or 20 mg/L/day melatonin, via drinking water (from PND 28–55) | Hilus, granular cell layer (GCL), and CA1 region of hippocampus | Melatonin increased number of BrdU+ proliferative cells in the hilus and increased number of NeuN+ neurons in the hilus and GCL in the irradiated PND23 rats Melatonin also increased number of NeuN+ neurons in the CA1 region of the irradiated PND 56 rats | Improved spatial memory (Morris water maze) | Reduced ROS levels in irradiated PND56 rats | Pipová Kokošová et al., 2020 [102] |
| 6–8-month-old rats exposed to a single dose of 25 Gy | 100 mg/kg BW melatonin, intraperitoneally injected 60 min before radiation exposure | Subventricular zone | Prevented cell apoptosis and reduced the decrease in Nestin+ cells | Not examined in the study | Increased antioxidant enzyme activity and decreased MDA levels | Naseri et al., 2017 [103] |
| Male 6-week-old C57BL mice exposed to 2 Gy of whole-body Fe irradiation | 10 mg/kg BW N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK), intraperitoneally injected 30 min before radiation exposure | Dentate gyrus | Prevented the loss of DCX+ neuronal precursor cells and Ki-67+ proliferative cells | Improved spatial memory impairment | Reduced protein oxidation (carbonyl content); reduced 4-hydroxyalkal + malondialdehyde (MDA+HAE) | Manda et al., 2008 [104] |
| 6-week-old male C57BL mice exposed to 6 Gy of cranial X-ray | 10 mg/kg BW melatonin, intraperitoneally injected 30 min before radiation exposure | Dentate gyrus | Prevented radiation-induced reduction in DCX+ neuronal precursor cells and Ki-67+ proliferative cells | Not examined in the study | 8-OHdG 4-HNE | Manda et al., 2009 [105] |
| Male 12-week-old Wistar albino rats exposed to a 900 MHz electromagnetic fields (EMF) | 50 mg/kg BW melatonin, intraperitoneally injected daily during EMF exposure | Hippocampus and cerebellum | Prevented EMF-induced cell loss | Prevented cognitive impairment (passive avoidance test) | Reduced SOD activity | Altun et al., 2017 [106] |
Dexamethasone (DEX) is a type of high potency corticosteroid medication. It causes depressive-like behavior and neurogenesis disruption in mice after exposure. It was found that pre-treatment of melatonin could prevent DEX-induced abnormality by modulating the glucocorticoid receptor (GR) and ERK1/2 expression [98]. The findings were further supported by an in vitro study, which showed that melatonin could reduce the DEX-induced decline in Ki67 and Nestin expression in the neurosphere of adult hippocampal NSCs by regulating the ERK1/2, cyclin E, and CDK2 via the melatonin and glucocorticoid receptors [107] (Tables 10 and 11).

### Table 11.

| Cells | Lowest Dosage Causing an Observable Effect | Main Findings | Molecular Mechanisms | References |
|-------|--------------------------------------------|---------------|----------------------|------------|
| Adult hippocampal NSCs (from 8-week-old rats) exposed to dexamethasone (DEX) | 1 µM melatonin, treated 30 min before 1 µM DEX treatment, for 5 days | Prevented DEX-induced reduction in Ki67 and Nestin expression in the neurosphere | Melatonin receptors and glucocorticoid receptor; reversed the DEX-induced changes in ERK1/2, cyclin E, and CDK2 | Ektusuwapranee et al., 2015 [107] |
| Mouse NSCs (E12.5) exposed to tri-ortho-cresyl phosphate (TOCP) | 40 µM melatonin, treated before TOCP exposure for 24 h | Prevented the decrease in cell viability after TOCP exposure | Reduced production of ROS; restored ERK1/2 signaling pathway | Liu et al., 2020 [108] |

In addition, melatonin also protected against the behavioral impairments caused by morphine sulfate and ketamine in rats and mice [99,100]. It was found that the protective effects were brought by the upregulation of BDNF and modulation of the MEK/ERK and PI3K/AKT signaling pathways [100]. However, the roles of melatonin on the neurogenesis regulation in the morphine sulfate- and ketamine-exposed animals have not yet been sufficiently studied (Table 10).

Environmental toxicants such as insecticide and industrial chemicals affect neurodevelopment. Exposure of fenvalerate (FEN) 5 h after fertilization caused abnormal swimming behavior in zebrafish [101]. However, melatonin could prevent the FEN-induced abnormal behavior and neurogenesis disruption by suppressing the pro-apoptotic genes such as Bax, Fas, caspase 8, caspase 9, and caspase 3 and upregulating the anti-apoptotic genes such as Bcl-2 [101]. Tri-ortho-cresyl phosphate (TOCP) is a material that is widely used in industries. Melatonin protected the mouse E12.5 NSCs from TOCP-induced cell death by suppressing the ROS levels and activating the ERK1/2 signaling pathway [108] (Tables 10 and 11).

Radiation and electromagnetic fields also affected spatial memory and cognitive functions in the rats and mice [102–106]. Melatonin or its metabolite N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) reduced the oxidative stress levels, improved neurogenesis, and further enhanced the behavioral outcomes of the animals after the exposure of radiation and electromagnetic fields [102–106] (Table 10).

Collectively, the findings suggest that melatonin exerts protective effects on the environmental factor-induced neurological deficits by modulating neurogenesis.

### 9. Melatonin and Other Diseases That Are Related to Neurogenesis Impairment

Melatonin has been found to also attenuate neurogenesis impairment in a wide range of other diseases that were not discussed above.

As a metabolic disease, diabetes mellitus (DM) can lead to neurological problems chronically. A high fat diet (HFD) and streptozotocin (STZ)-induced DM led to neurogenesis and synaptogenesis deficits and impaired spatial memory in rats [109]. Melatonin, however, could reverse the adverse effects caused DM by activating the p-ERK signaling pathway and upregulating the melatonin receptor as well as insulin receptor [109] (Table 12).
Table 12. The main findings regarding the effects of melatonin on neurogenesis in other neurogenesis impairment-related diseases and the respective molecular mechanisms in the in vivo studies.

| Animals | Treatment Timeline and Dosage | Brain Regions | Main Findings | Behavioral Outcomes | Molecular Mechanisms | References |
|---------|-------------------------------|---------------|---------------|---------------------|----------------------|------------|
| Six-week-old male Wistar rats were fed with a high fat diet (HFD) and subjected to STZ (diabetes mellitus) | 10 mg/kgBW melatonin, subcutaneously injected for 4 weeks | Hippocampus | Reversed HFD + STZ-induced neurogenesis and synaptogenesis impairment | Reversed HFD + STZ-induced spatial memory impairment | Prevented suppression of melatonin receptor and insulin receptor; upregulated p-ERK | Wongchitrat et al., 2016 [109] |
| E11.5 and E17.5 embryos from 8-week-old pregnant Kunming mice subjected to streptozotocin (STZ) (diabetes mellitus) | 10 mg/kg BW melatonin, intraperitoneally injected into the pregnant mice (starting from E0.5 to the end of experiment) | Cortex | Prevented STZ-induced inhibition of NSC proliferation; Decreased STZ-induced premature differentiation of NSCs | Not examined in the study | Decreased autophagy | Li et al., 2019 [110] |
| E11.5 embryos from 8-week-old pregnant ICR mice which were subjected to STZ (diabetes mellitus) | 10 mg/kg BW melatonin, intraperitoneally injected into pregnant mice (starting from E0.5 to the end of the experiment) | Forebrain | Prevented STZ-induced reduction in proliferation of NSCs | Not examined in the study | Not examined in the study | Liu et al., 2015 [111] |
| 6–6.5-month-old Ts65Dn (TS) mice (Down syndrome) | 100 mg/L melatonin, via drinking water from 6–6.5 months old to 11–12 months old | Hippocampus | Reversed neurogenesis impairment | Decreased reduction in the density of hippocampal granule cells | Increased density and activity of glutamatergic synapses; decreased the levels of lipid peroxidation | Corrales et al., 2014 [112] |
| Ts65Dn (TS) mice (Down syndrome) | 100 mg/L melatonin, treated via drinking water from the time of conception of the mouse mothers to the age of 5 months of the offspring | Hippocampus and cortex | Did not reverse the decrease in cell proliferation in the TS mice But regulated brain oxidative stress | No effects on behavioral outcomes | Modulated the activity of antioxidant enzymes (superoxide dismutase and catalase); decreased the levels of lipid peroxidation | Corrales et al., 2017 [113] |
| PND 0 rats from rat mothers subjected to seizures induction on E13 of the pregnancy (epilepsy) | 30 µg/100 g BW melatonin, intraperitoneally injected into the rat mothers for 2 months | Cerebellum | Inhibited epilepsy-induced increase in Nestin expression | Not examined in the study | Not examined in the study | Uyanikgil et al., 2005 [114] |
| PND 0 rats from rat mothers subjected to seizure induction on E13 of the pregnancy and pinealectomy 1 month before seizures induction (epilepsy) | 30 µg/100 g BW melatonin, subcutaneously injected into the rat mothers for 2 months (starting from the date of pinealectomy surgery) | CA1 region of the hippocampus | Inhibited pinealectomy-stimulated increase in Nestin expression | Not examined in the study | Not examined in the study | Turgut et al., 2006 [115] |
DM also causes fetal neurodevelopmental impairment. When female mice were subjected to STZ before pregnancy for 3 consecutive days and then fertilized with healthy male mice, the E11.5 and E17.5 mouse embryos showed decreased proliferation and increased premature differentiation of NSCs in the brain [110]. Nevertheless, melatonin could attenuate the STZ-induced neurodevelopmental deficits by inhibiting autophagy and preventing apoptosis in the embryonic brain [110,111]. In the in vitro experiments, it was also reported that melatonin could protect the embryonic NSCs from cell death and impairments in proliferation and differentiation in the hyperglycemia condition [110,111] (Tables 12 and 13).

**Table 13.** Table showing the main findings regarding the effects of melatonin on neurogenesis in other neurogenesis impairment-related diseases and the respective molecular mechanisms in the in vitro studies.

| Cells | Lowest Dosage Causing an Observable Effect | Main Findings | Molecular Mechanisms | References |
|-------|-------------------------------------------|---------------|----------------------|------------|
| Mouse cortical NSCs (E12.5) subjected to hyperglycemia | 10 nM melatonin, treated for 24 h | Promoted proliferation and self-renewal of NSCs in hyperglycemia | Decreased autophagy; activated mTOR signaling pathway | Li et al., 2019 [110] |
| Mouse telencephalon NSCs (E11.5) subjected to hyperglycemia | 100 nM melatonin, treated for 3 days | Prevented hyperglycemia-induced inhibition of NSC proliferation | ERK signaling pathway | Liu et al., 2015 [111] |
| Olfactory NSCs from a 28-year-old male patient diagnosed with schizophrenia (SCZ) | $10^{-5}$ M melatonin, treated for 12 h | Attenuated the SCZ induced-abnormal increase in potassium-evoked secretion | Not examined in the study | Cercós et al., 2017 [116] |

Ts65Dn (TS) mice are a commonly used model of DS, which were found to exhibit different DS phenotypes including cognitive deficits and impairments in hippocampal functions [112]. It was reported that melatonin rescued the neurogenesis suppression in the Ts65Dn (TS) mice by increasing the density and activity of glutamatergic synapses [112]. Nevertheless, in another study, it was shown that melatonin had no effect on the improvement of neurogenesis and behavioral outcomes in TS mice, but only regulated the DS-induced oxidative stress [113] (Table 12).

Seizures impair neurogenesis. Induction of seizures to a rat mother led to early embryonic neurogenesis and delayed maturation of newborn neurons in the cerebellum and the Cornus ammonis 1 (CA1) region of the hippocampus in PND0 offspring [114,115]. Olfactory NSCs isolated from schizophrenia (SCZ) patients also exhibited an abnormal increase in the potassium-evoked secretion when compared with the NSCs of the healthy control [116]. Interestingly, melatonin treatment could reverse all the abnormalities caused by seizures [114–116] (Tables 12 and 13).

**10. Melatonin and Peripheral Nerve Impairment**

Apart from rescuing neurogenesis impairment in the CNS, melatonin also promotes nerve regeneration after peripheral nerve injury (PNI).

Studies showed that 30-day 1 and 10 mg/kg BW melatonin treatment could promote nerve regeneration in the rats after PNI [117,118]. It was also found that melatonin improved the upper limb functional recovery and restored the number of re-innervated motor end plates on the target muscle in the rats after PNI [117]. The protection of melatonin against PNI was suggested to be brought by the suppression of CaMKII [117]. It was also suggested that the protective effects may be related to the increase of proliferation of the Schwann cells after the melatonin treatment, given that Schwann cells are crucial for axonal guidance and nerve regeneration after PNI [118]. Melatonin was shown to promote proliferation of Schwann cells by activating ERK 1/2 via the MT1 receptor [118] (Table 14).
Table 14. Table showing the main findings regarding the effects of melatonin on peripheral nerve impairment and the respective molecular mechanisms in the in vivo studies.

| Animals | Treatment Timeline and Dosage | Targets | Main Findings | Behavioral Outcomes | Molecular Mechanisms | References |
|---------|-------------------------------|---------|---------------|---------------------|----------------------|------------|
| Young adult male Wistar rats subjected to PNI (ESN) | 1 mg/kg BW melatonin, intraperitoneally injected daily for 1 month after ESN | Peripheral nerve tissue | Enhanced expression of GAP43 and β3-tubulin | Enhanced upper limb functional recovery | Melatonin receptors (MT1/MT2) Suppressed CaMKII | Liu et al., 2020 [117] |
| Young adult male Wistar rats subjected to peripheral nerve injury (PNI), which was performed by end-to-side neurorrhaphy (ESN) | 1 and 10 mg/kg BW melatonin, intraperitoneally injected daily for 30 days | Nerves on target muscle | Improved nerve regeneration | Not examined in the study | Increased proliferation of Schwann cells (MT1 and phosphorylation of ERK 1/2) | Chang et al., 2014 [118] |
| Adult male Wistar subjected to hypoglossal nerve transection (PNI) | 5 or 100 mg/kg BW melatonin, intraperitoneally injected daily for 3, 7, 14, 21, and 30 days | Hypoglossal nucleus | Increased number of motoneurons in the hypoglossal nucleus | Not examined in the study | Suppressed NADPH-d/NOS expression | Chang et al., 2000 [119] |
| Adult male Wistar rats subjected to hypoglossal nerve transection (PNI) | 5 or 100 mg/kg BW melatonin, intraperitoneally injected daily for 3, 7, 14, 30, or 60 days | Hypoglossal motoneurons | Preserved activities of Mn-SOD, Cu/Zn-SOD, and ChAT | Promoted functional recovery | Suppressed nNOS augmentation | Chang et al., 2008 [120] |
| SD rats subjected to chronic constriction injury | 5 mg/kg and 10 mg/kg melatonin, intraperitoneally injected on the 14th day after surgery | Dorsal root ganglia | Modulation of the nitroxidergic system | Improvement in thermal hyperalgesia | Modulated iNOS and nNOS levels | Borsani et al., 2017 [121] |
| SD rats exposed to oxaliplatin (peripheral neuropathy) | 3 or 10 mg/kg BW melatonin, intraperitoneally injected for 28 days | Sciatic nerve and dorsal root ganglia | Ameliorated oxidative/nitrosative stress mediated by oxaliplatin Induced autophagy and inhibited apoptosis | Relieved oxaliplatin-induced pain behavior and neuropathic deficits (cold chemical allodynia, mechanical allodynia, and mechanical hyperalgesia) | Reduced the changes in the levels of MDA nitrite, GSH, nitrotyrosine, and MnSOD Inhibited apoptotic pathway (Bcl2, BAX, caspase 3, and cytochrome C) Autophagy pathway (LC3A/B-I and II, beclin, Atg 3, Atg 5, and Atg 7) | Aneti et al., 2017 [122] |
| Adult male Wistar rats subjected to ischemia–reperfusion (IR) injury | 10 mg/kg BW melatonin, injected via tail vein immediately before the reperfusion period | Sciatic nerve | Salvaged the nerve fibers from ischemic degeneration Decreased edema and damage in the myelin sheaths and axons | Not examined in the study | Reversed the IR-induced increase in MDA levels Increased SOD levels | Sayan et al., 2004 [123] |
| Female Wistar rats subjected to cut or crush injury | 50 mg/kg BW melatonin, intraperitoneally injected after sciatic nerve injury | Sciatic nerve | Preserved myelin sheath | Not examined in the study | Decreased lipid peroxidation Increased SOD, CAD, and GPx activity | Kaya et al., 2013 [124] |
| Adult male Wistar rats subjected to pinealectomy 3 weeks before surgical intervention consisting of bilateral sciatic nerve section and primary suture repair | 30 mg/100 g BW melatonin, subcutaneously injected after pinealectomy | Sciatic nerve/epineurium | Increased collagen content of the sciatic nerve and macroscopic neuroma formation after pinealectomy but the elevation was reversed by the melatonin treatment Melatonin treatment reduced the elevation of the Type I collagen and Type III collagen in epineurium after pinealectomy | Not examined in the study | Not examined in the study | Turgut et al., 2005 [125] |
The modulation of the nitroxidergic system plays an important role in the protective effects of melatonin on nerve injury. After rats were subjected to hypoglossal nerve transection, melatonin suppressed NADPH-d/NOS expression and preserved superoxide dismutase (SOD) activity, which increased the number of motoneurons in the hypoglossal nucleus and further improved the functional recovery [119,120]. Chronic constriction injury (CCI) is an injury model that causes peripheral neuropathic pain on the sciatic nerve in animals. One study showed that melatonin modulated the iNOS and nNOS levels in the dorsal root ganglia, which alleviated thermal nociceptive hypersensitivity in rats after CCI [121]. Oxaliplatin is a compound that is used in the treatment of colorectal cancer but it has the side effect of causing peripheral neuropathy [122]. Melatonin, moreover, was found to modulate the nitroxidergic system in oxaliplatin-treated rats. It helped reduce the oxaliplatin-induced pain behavior and neuropathic deficits by alleviating nitrosative stress [122]. Apart from regulating the nitroxidergic system, melatonin also inhibited the apoptotic pathway and activated the autophagy pathway in the sciatic nerve and dorsal root ganglia in oxaliplatin-treated rats [122] (Table 14).

Due to its antioxidant properties, melatonin promoted nerve recovery after ischemia–reperfusion (I/R) injury. Melatonin salvaged the nerve fibers from ischemic degeneration and it decreased edema and damage in the myelin sheaths and axons after the I/R injury by reversing the I/R-induced increase in the MDA levels [123]. In the cut or crush sciatic nerve injury model, melatonin also preserved myelin sheath in the injured rats by decreasing lipid peroxidation, which helped promote the recovery [124]. In both injury models, melatonin treatment increased the SOD levels [123,124] (Table 14).

Last but not least, the roles of melatonin of nerve regeneration were further confirmed by the pinealectomy experiment, in which pinealectomy was performed in the rats 3 weeks before they were subjected to a surgical intervention consisting of bilateral sciatic nerve section and primary suture repair [125]. The results showed that the collagen content of the sciatic nerve and macroscopic neuroma formation increased in pinealectomy rats, but melatonin treatment reversed the changes [125]. Moreover, melatonin also helped reduce the stimulus intensities required to excite a nerve action potential response (NAP) in the pinealectomy rats [125] (Table 14).

11. Conclusions

From the traditional biological perspective, melatonin is well recognized as a key player of regulating circadian rhythm. Recent studies, however, have highlighted the pleiotropic nature of melatonin, which is widely related to the normal functioning of different systems, including the CNS. Due to its diverse effects, the melatonin signaling system could be a possible treatment target of disorders of the CNS. As increasing evidence has shown that melatonin is pro-neurogenic, it is a possible drug candidate that may be used for treating neurogenesis-related disorders, such as mood disorders, neurotrauma, and neurodegenerative disorders. However, as the neurogenic and treatment effect of melatonin has been just discovered in the past two decades, its potential as a drug remains to be further confirmed and explored.

Further exploration of the signaling mechanisms, treatment effect of the synthetic agonist/antagonist on different disorders, and potential side effects are possible future study directions in terms of applying melatonin in treating various CNS disorders. The lack of severe side effects and the affordable nature of melatonin would imply its applicability in clinical situations for chronic treatment.

Author Contributions: Conception or design of the work: J.W.-H.L. and B.W.-M.L.; drafting the article: J.W.-H.L.; critical revision of the article: K.-K.C., S.P.-C.N., H.W.-H.T. and B.W.-M.L.; final approval of submission/publication: H.W.-H.L. and B.W.-M.L. All authors have read and agreed to the published version of the manuscript.

Funding: The work is supported by the General Research Fund to B.W.-M.L. (No. 15164216) and Seed Fund to B.W.-M.L. by the department of RS, PolyU (P0033496/ZVR7).

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Altman, J.; Das, G.D. Postnatal neurogenesis in the guinea-pig. Nature 1967, 214, 1098–1101. [CrossRef]
2. Malberg, J.E.; Eisch, A.J.; Nestler, E.J.; Duman, R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 2000, 20, 9104–9110. [CrossRef]
3. Ming, G.-L.; Song, H. Adult neurogenesis in the mammalian brain: Significant answers and significant questions. Neuron 2011, 70, 687–702. [CrossRef]
4. Alvarez-Buylla, A.; Garcia-Verdugo, J.M. Neurogenesis in adult subventricular zone. J. Neurosci. 2002, 22, 629–634. [CrossRef]
5. Sakamoto, M.; Imayoshi, I.; Ohtsuka, T.; Yamaguchi, M.; Mori, K.; Kageyama, R. Continuous neurogenesis in the adult forebrain is required for innate olfactory responses. Proc. Natl. Acad. Sci. USA 2011, 108, 8479–8484. [CrossRef]
6. Balu, D.T.; Lucki, I. Adult hippocampal neurogenesis: Regulation, functional implications, and contribution to disease pathology. Neurosci. Biobehav. Rev. 2009, 33, 232–252. [CrossRef]
7. Sahay, A.; Scobie, K.N.; Hill, A.S.; O’Carroll, C.M.; Kheirbek, M.A.; Burghardt, N.S.; Fenton, A.A.; Dranovsky, A.; Hen, R. Increasing adult hippocampal neurogenesis is sufficient to improve pattern separation. Nature 2011, 472, 466–470. [CrossRef]
8. Leung, J.W.-H.; Lau, W.; Lau, B.W.-M.; Yee, B. A Commentary on the Therapeutic Potential of Melatonin and Its Analogues in CNS Conditions: From Translational Research to a Humanistic Approach—Volume III; Springer: Cham, Switzerland, 2019; pp. 177–186. ISBN 978-3-319-95539-5.
9. Tan, D.-X.; Manchester, L.C.; Liu, X.; Rosales-Corral, S.A.; Acuna-Castroviejo, D.; Reiter, R.J. Mitochondria and chloroplasts as the original sites of melatonin synthesis: A hypothesis related to melatonin’s primary function and evolution in eukaryotes. J. Pineal Res. 2013, 54, 127–138. [CrossRef]
10. Tan, D.-X.; Reiter, R.J. Mitochonidia: The birth place, battle ground and the site of melatonin metabolism in cells. Melatonin Res. 2019, 2, 44–66. [CrossRef]
11. Reiter, R.J.; Tan, D.X.; Rosales-Corral, S.; Galano, A.; Zhou, X.J.; Xu, B. Mitochondria: Central Organelles for Melatonin’s Antioxidant and Anti-Aging Actions. Molecules 2018, 23, 509. [CrossRef]
12. Li, D.Y.; Smith, D.G.; Hardeland, R.; Yang, M.Y.; Xu, H.L.; Zhang, L.; Yin, H.D.; Zhu, Q. Melatonin receptor genes in vertebrates. Int. J. Mol. Sci. 2013, 14, 11208–11223. [CrossRef] [PubMed]
13. Stein, R.M.; Kang, H.J.; McCorvy, J.D.; Glattfelter, G.C.; Jones, A.J.; Che, T.; Slocum, S.; Huang, X.-P.; Savych, O.; Moroz, Y.S.; et al. Virtual discovery of melatonin receptor ligands to modulate circadian rhythms. Nature 2020, 579, 609–614. [CrossRef] [PubMed]
14. González-Arto, M.; Aguilar, D.; Gaspar-Torrueba, E.; Gallego, M.; Carvajal-Serna, M.; Herrera-Marcos, L.V.; Serrano-Blesa, E.; Hamilton, T.R.D.S.; Pérez-Pé, R.; Muñoz-Blanco, T.; et al. Melatonin MT1 and MT2 Receptors in the Ram Reproductive Tract. Int. J. Mol. Sci. 2017, 18, 662. [CrossRef] [PubMed]
15. Masana, M.I.; Doolen, S.; Ershahin, C.; Al-Ghoul, W.M.; Dukles, S.P.; Dubocovich, M.L.; Krause, D.N. MT(2) melatonin receptors are present and functional in rat caudal artery. J. Pharmacol. Exp. Ther. 2002, 302, 1295–1302. [CrossRef] [PubMed]
16. Carrillo-Vico, A.; Lardone, P.J.; Alvarez-Sánchez, N.; Rodríguez-Rodriguez, A.; Guerrero, J.M. Melatonin: Buffering the immune system. Int. J. Mol. Sci. 2013, 14, 8638–8683. [CrossRef] [PubMed]
17. Monteiro, M.C.; Coleman, M.D.; Hill, E.J.; Prediger, R.D.; Maia, C.S.F. Neuroprotection in Neurodegenerative Disease: From Basic Science to Clinical Applications. Oxid. Med. Cell. Longev. 2017, 2017, 2949102. [CrossRef]
18. Vincent, B. Protective roles of melatonin against the amyloid-dependent development of Alzheimer’s disease: A critical review. Pharmacol. Res. 2018, 134, 223–237. [CrossRef]
19. Alghamdi, B.S. The neuroprotective role of melatonin in neurological disorders. J. Neurosci. Res. 2018, 96, 1136–1149. [CrossRef]
20. Suofu, Y.; Li, W.; Jean-Alphonse, F.G.; Jia, J.; Khattar, N.K.; Li, J.; Baranov, S.V.; Leronn, D.; Mihali, A.C.; He, Y.; et al. Dual role of mitochondria in producing melatonin and driving GPCR signaling to block cytochrome c release. Proc. Natl. Acad. Sci. USA 2017, 114, E7997–E8006. [CrossRef]
21. Sarlak, G.; Jenwitheesuk, A.; Chetsawang, B.; Govitrapong, P. Effects of melatonin on nervous system aging: Neurogenesis and neurodegeneration. J. Pharmacol. Sci. 2013, 123, 9–24. [CrossRef]
22. Ghareghani, M.; Sadeghi, H.; Zibara, K.; Danaei, N.; Azari, H.; Ghanbari, A. Melatonin increases oligodendrocyte differentiation in cultured neural stem cells. *Cell. Mol. Neurobiol.* 2017, 37, 1319–1324. [CrossRef]

23. Li, X.; Chen, X.; Zhou, W.; Ji, S.; Li, X.; Li, G.; Liu, G.; Wang, F.; Hao, A. Effect of melatonin on neuronal differentiation requires CBP/p300-mediated acetylation of histone H3 lysine 14. *Neuroscience* 2017, 364, 45–59. [CrossRef]

24. Figueiro-Silva, J.; Antequera, D.; Pascual, C.; de la Fuente Revenga, M.; Volt, H.; Acuña-Castroviejo, D.; Rodriguez-Franco, M.I.; Carro, E. The Melatonin Analog IQM316 May Induce Adult Hippocampal Neurogenesis and Preserve Recognition Memories in Mice. *Cell Transpl.* 2018, 27, 423–437. [CrossRef]

25. Liu, Y.; Zhang, Z.; Lv, Q.; Chen, X.; Deng, W.; Shi, K.; Pan, L. Effects and mechanisms of melatonin on the proliferation and neural differentiation of PC12 cells. *Biochem. Biophys. Res. Commun.* 2016, 478, 540–545. [CrossRef] [PubMed]

26. Sharma, R.; Ottenhof, T.; Rzeczowska, P.A.; Niles, L.P. Epigenetic targets for melatonin: Induction of histone H3 hyperacetylation and gene expression in C17.2 neural stem cells. *J. Pineal Res.* 2008, 45, 277–284. [CrossRef]

27. Kong, X.; Li, X.; Cai, Z.; Yang, N.; Liu, Y.; Shu, J.; Pan, L.; Zuo, P. Melatonin regulates the viability and differentiation of rat midbrain neural stem cells. *Cell. Mol. Neurobiol.* 2008, 28, 569–579. [CrossRef] [PubMed]

28. Moirya, T.; Horie, N.; Mitome, M.; Shinohara, K. Melatonin influences the proliferative and differentiative activity of neural stem cells. *J. Pineal Res.* 2007, 42, 411–418. [CrossRef] [PubMed]

29. Phonchai, R.; Phermthai, T.; Kitiyanant, N.; Suwanjang, W.; Kotchabhakdi, N.; Chetsawang, B. Potential effects and molecular mechanisms of melatonin on the dopaminergic neuronal differentiation of human amniotic fluid mesenchymal stem cells. *Neurochem. Int.* 2019, 124, 82–93. [CrossRef] [PubMed]

30. Shu, T.; Wu, T.; Pang, M.; Liu, C.; Wang, X.; Wang, J.; Liu, B.; Rong, L. Effects and mechanisms of melatonin on neural differentiation of induced pluripotent stem cells. *Biochem. Biophys. Res. Commun.* 2016, 474, 566–571. [CrossRef]

31. Domínguez-Alonso, A.; Ramírez-Rodriguez, G.; Benítez-King, G. Melatonin increases dendritogenesis in the hilus of hippocampal organotypic cultures. *J. Pineal Res.* 2012, 52, 427–436. [CrossRef] [PubMed]

32. Domínguez-Alonso, A.; Valdés-Tovar, M.; Solís-Chagoyán, H.; Benítez-King, G. Melatonin stimulates dendrite formation and complexity in the hilar zone of the rat hippocampus: Participation of the Ca++/Calmodulin complex. *Int. J. Mol. Sci.* 2015, 16, 1907–1927. [CrossRef] [PubMed]

33. Ramírez-Rodriguez, G.; Klempin, F.; Babu, H.; Benítez-King, G.; Kempermann, G. Melatonin modulates cell survival of new neurons in the hippocampus of adult mice. *Neuropsychopharmacology* 2009, 34, 2180–2191. [CrossRef]

34. Sotthibundhu, A.; Phansuwan-Pujito, P.; Govitrarong, P. Melatonin increases proliferation of cultured neural stem cells obtained from adult mouse subventricular zone. *J. Pineal Res.* 2010, 49, 291–300. [CrossRef] [PubMed]

35. Sotthibundhu, A.; Ekthuwapranee, K.; Govitrarong, P. Comparison of melatonin with growth factors in promoting precursor cells proliferation in adult mouse subventricular zone. *EXCLI J.* 2016, 15, 829–841. [CrossRef]

36. Tocharus, C.; Puriboriboony, Y.; Junmanee, T.; Tocharus, J.; Ekthuwapranee, K.; Govitrarong, P. Melatonin enhances adult rat hippocampal progenitor cell proliferation via ERK signaling pathway through melatonin receptor. *Neuroscience* 2014, 253, 314–321. [CrossRef]

37. Yu, S.; Zhang, X.; Xu, Z.; Hu, C. Melatonin promotes proliferation of neural stem cells from adult mouse spinal cord via the PI3K/AKT signaling pathway. *FEBS Lett.* 2019, 593, 1751–1762. [CrossRef]

38. Ramírez-Rodriguez, G.; Ortiz-López, L.; Domínguez-Alonso, A.; Benítez-King, G.A.; Kempermann, G. Chronic treatment with melatonin stimulates dendrite maturation and complexity in adult hippocampal neurogenesis of mice. *J. Pineal Res.* 2011, 50, 29–37. [CrossRef]

39. Ramírez-Rodriguez, G.B.; Oller-Hernández, S.; Vega-Rivera, N.M.; Ortiz-López, L. Melatonin influences structural plasticity in the axons of granule cells in the dentate gyrus of Balb/C mice. *Int. J. Mol. Sci.* 2018, 20, 73. [CrossRef]

40. Rennie, K.; De Butte, M.; Pappas, B.A. Melatonin promotes neurogenesis in dentate gyrus in the pinealectomized rat. *J. Pineal Res.* 2009, 47, 313–317. [CrossRef]
41. Motta-Teixeira, L.C.; Machado-Nils, A.V.; Battagello, D.S.; Diniz, G.B.; Andrade-Silva, J.; Silva, S.; Matos, R.A.; do Amaral, F.G.; Xavier, G.F.; Bittencourt, J.C., et al. The absence of maternal pineal melatonin rhythm during pregnancy and lactation impairs offspring physical growth, neurodevelopment, and behavior. *Horm. Behav.* **2018**, *105*, 146–156. [CrossRef]

42. Ramírez-Rodriguez, G.; Vega-Rivera, N.M.; Benítez-King, G.; Castro-García, M.; Ortiz-López, L. Melatonin supplementation delays the decline of adult hippocampal neurogenesis during normal aging of mice. *Neurosci. Lett.* **2012**, *530*, 53–58. [CrossRef] [PubMed]

43. Ramírez-Rodriguez, G.; Gómez-Sánchez, A.; Ortiz-López, L. Melatonin maintains calcium-binding calretinin-positive neurons in the dentate gyrus during aging of Balb/C mice. *Exp. Gerontol.* **2014**, *60*, 147–152. [CrossRef] [PubMed]

44. Liu, J.; Somera-Molina, K.C.; Hudson, R.L.; Dubocovich, M.L. Melatonin potentiates running wheel-induced neurogenesis in the dentate gyrus of adult C3H/HeN mice hippocampus. *J. Pineal Res.* **2013**, *54*, 222–231. [CrossRef]

45. Ortiz-López, L.; Pérez-Beltran, C.; Ramírez-Rodríguez, G. Chronic administration of a melatonin membrane receptor antagonist, luzindole, affects hippocampal neurogenesis without changes in hopelessness-like behavior in adult mice. *Neuropharmacology* **2016**, *103*, 211–221. [CrossRef] [PubMed]

46. Liao, L.-Y.; Lau, B.W.-M.; Sánchez-Vidaña, D.I.; Gao, Q. Exogenous neural stem cell transplantation for cerebral ischemia. *Neural Regen. Res.* **2019**, *14*, 1129–1137. [CrossRef] [PubMed]

47. Miller, B.R.; Hen, R. The current state of the neurogenic theory of depression and anxiety. *Curr. Opin. Neurobiol.* **2015**, *30*, 51–58. [CrossRef]

48. Chan, J.N.-M.; Lee, J.C.-D.; Lee, S.S.P.; Hui, K.K.Y.; Chan, A.H.L.; Fung, T.K.-H.; Somera-Molina, K.C.; Hudson, R.L.; Dubocovich, M.L. Melatonin potentiates running wheel-induced neurogenesis without changes in hopelessness-like behavior in adult mice. *Neuropharmacology* **2016**, *103*, 211–221. [CrossRef] [PubMed]

49. Liao, L.-Y.; Lau, B.W.-M.; Sánchez-Vidaña, D.I.; Gao, Q. Exogenous neural stem cell transplantation for cerebral ischemia. *Neural Regen. Res.* **2019**, *14*, 1129–1137. [CrossRef] [PubMed]

50. Ramírez-Rodriguez, G.B.; Palacios-Cabriales, D.M.; Ortiz-López, L.; Estrada-Camarena, E.M.; Vega-Rivera, N.M. Melatonin modulates dendrite maturation and complexity in the dorsal- and ventral-dentate gyrus concomitantly with its antidepressant-like effect in male Balb/C mice. *Int. J. Mol. Sci.* **2020**, *21*, 1724. [CrossRef]

51. Crupi, R.; Mazzon, E.; Marino, A.; La Spada, G.; Bramanti, P.; Cuzzocrea, S.; Spina, E. Melatonin treatment mimics the antidepressant action in chronic corticosterone-treated mice. *J. Pineal Res.* **2010**, *49*, 123–129. [CrossRef] [PubMed]

52. Hoehn, R.; Monse, M.; Pohl, E.; Wranik, S.; Wilker, B.; Keitsch, S.; Soeddemann, M.; Kornhuber, J.; Kohnen, M.; Edwards, M.J.; et al. Melatonin acts as an antidepressant by inhibition of the acid sphingomyelinase/ceramide system. *Neurosignals* **2016**, *24*, 48–58. [CrossRef] [PubMed]

53. Stefanovic, B.; Spasovic, N.; Jovanovic, P.; Jasnic, N.; Djordjevic, J.; Dronjak, S. Melatonin mediated antidepressant-like effect in the hippocampus of chronic stress-induced depression rats: Regulating vesicular monoamine transporter 2 and monoamine oxidase A levels. *Eur. Neuropsychopharmacol.* **2016**, *26*, 1629–1637. [CrossRef] [PubMed]

54. Ramírez-Rodríguez, G.; Vega-Rivera, N.M.; Oikawa-Sala, J.; Gómez-Sánchez, A.; Ortiz-López, L.; Estrada-Camarena, E. Melatonin synergizes with citolopram to induce antidepressant-like behavior and to promote hippocampal neurogenesis in adult mice. *J. Pineal Res.* **2014**, *56*, 450–461. [CrossRef] [PubMed]

55. Morley-Fletcher, S.; Mairesse, J.; Soumier, A.; Banasr, M.; Fagioli, F.; Gabriel, C.; Mocaer, E.; Daszuta, A.; McEwen, B.; Nicoletti, F.; et al. Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats. *Psychopharmacology* **2011**, *217*, 301–313. [CrossRef] [PubMed]

56. Yucel, A.; Yucel, N.; Ozkanlar, S.; Polat, E.; Kara, A.; Ozcan, H.; Gulec, M. Effect of agomelatine on adult hippocampus apoptosis and neurogenesis using the stress model of rats. *Acta Histochem.* **2016**, *118*, 299–304. [CrossRef]

57. AlAhmed, S.; Herbert, J. Effect of agomelatine and its interaction with the daily corticosterone rhythm on progenitor cell proliferation in the dentate gyrus of the adult rat. *Neuropharmacology* **2010**, *59*, 375–379. [CrossRef]
58. Soumier, A.; Banasr, M.; Lortet, S.; Masmejean, F.; Bernard, N.; Kerkerian-Le-Goff, L.; Gabriel, C.; Millan, M.J.; Mocaer, E.; Daszuta, A. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. *Neuropsychopharmacology* 2009, 34, 2390–2403. [CrossRef]

59. Yoo, D.Y.; Kim, W.; Lee, C.H.; Shin, B.N.; Nam, S.M.; Choi, J.H.; Won, M.-H.; Yoon, Y.S.; Hwang, I.K. Melatonin improves D-galactose-induced aging effects on behavior, neurogenesis, and lipid peroxidation in the mouse dentate gyrus via increasing pCREB expression. *J. Pineal Res.* 2012, 52, 21–28. [CrossRef]

60. Takeda, T.; Hosokawa, M.; Higuchi, K. Senescence-accelerated mouse (SAM): A novel murine model of accelerated senescence. *J. Am. Geriatr. Soc.* 1991, 39, 911–919. [CrossRef]

61. Gutierrez-Cuesta, J.; Tajes, M.; Jiménez, A.; Coto-Montes, A.; Camins, A.; Pallás, M. Evaluation of potential pro-survival pathways regulated by melatonin in a murine senescence model. *J. Pineal Res.* 2008, 45, 497–505. [CrossRef]

62. Singhakumar, R.; Boontem, P.; Ekthuwapranee, K.; Sotthibundhu, A.; Mukda, S.; Chetsawang, B.; Govitrapong, P. Melatonin attenuates methamphetamine-induced inhibition of neurogenesis in the adult mouse hippocampus: An in vivo study. *Neurosci. Lett.* 2015, 606, 209–214. [CrossRef] [PubMed]

63. Mendivil-Perez, M.; Soto-Mercado, V.; Guerra-Librero, A.; Fernandez-Gil, B.L.; Florido, J.; Shen, Y.-Q.; Tejada, M.A.; Capilla-Gonzalez, V.; Rusanova, I.; Garcia-Verdugo, J.M.; et al. Melatonin enhances neural stem cell differentiation and engraftment by increasing mitochondrial function. *J. Pineal Res.* 2017, 63, e12415. [CrossRef] [PubMed]

64. Sharma, R.; McMillan, C.R.; Niles, L.P. Neural stem cell transplantation and melatonin treatment in a 6-hydroxydopamine model of Parkinson’s disease. *J. Pineal Res.* 2007, 43, 245–254. [CrossRef] [PubMed]

65. Kim, W.; Hahn, K.R.; Jung, H.Y.; Kwon, H.J.; Choi, J.H.; Park, J.H.; Yoo, D.Y.; Kim, D.W.; Won, M.-H.; et al. Melatonin ameliorates cuprizone-induced reduction of hippocampal neurogenesis, brain-derived neurotrophic factor, and phosphorylation of cyclic AMP response element-binding protein in the mouse dentate gyrus. *Brain Behav.* 2019, 9, e01388. [CrossRef] [PubMed]

66. Song, C.; Li, M.; Xu, L.; Shen, Y.; Yang, H.; Ding, M.; Liu, X.; Xie, Z. Mitochondrial biogenesis mediated by melatonin in an APPsw/Ps1dE9 transgenic mouse model. *Neuroreport* 2018, 29, 1517–1524. [CrossRef]

67. Olson, M.; Lockhart, T.E.; Lieberman, A. Motor Learning Deficits in Parkinson’s Disease (PD) and Their Effect on Training Response in Gait and Balance: A Narrative Review. *Front. Neurol.* 2019, 10, 62. [CrossRef]

68. Ekthuwapranee, K.; Sotthibundhu, A.; Govitrapong, P. Melatonin attenuates methamphetamine-induced inhibition of proliferation of adult rat hippocampal progenitor cells in vitro. *J. Pineal Res.* 2015, 58, 418–428. [CrossRef]

69. Chern, C.-M.; Liao, J.-F.; Wang, Y.-H.; Shen, Y.-C. Melatonin ameliorates neural function by promoting endogenous neurogenesis through the MT2 melatonin receptor in ischemic-stroke mice. *Free Radic. Biol. Med.* 2012, 52, 1634–1647. [CrossRef]

70. Zhao, Y.; Wang, H.; Chen, W.; Chen, L.; Liu, D.; Wang, X.; Wang, X. Melatonin attenuates white matter damage after focal brain ischemia in rats by regulating the TLR4/NF-κB pathway. *Brain Res. Bull.* 2019, 150, 168–178. [CrossRef]

71. Kilic, E.; Kilic, U.; Bacigaluppi, M.; Guo, Z.; Abdallah, N.B.; Wolfer, D.P.; Reiter, R.J.; Hermann, D.M.; Bassetti, C.L. Delayed melatonin administration promotes neuronal survival, neurogenesis and motor recovery, and attenuates hyperactivity and anxiety after mild focal cerebral ischemia in mice. *J. Pineal Res.* 2008, 45, 142–148. [CrossRef]

72. Rennie, K.; de Butte, M.; Fréchette, M.; Pappas, B.A. Chronic and acute melatonin effects in gerbil global forebrain ischemia: Long-term neural and behavioral outcome. *J. Pineal Res.* 2008, 44, 149–156. [CrossRef] [PubMed]

73. Tang, Y.; Cai, B.; Yuan, F.; He, X.; Lin, X.; Wang, J.; Wang, Y.; Yang, G.-Y. Melatonin pretreatment improves the survival and function of transplanted mesenchymal stem cells after focal cerebral ischemia. *Cell Transpl.* 2014, 23, 1279–1291. [CrossRef] [PubMed]

74. Lee, Y.; Lee, S.; Lee, S.-R.; Park, K.; Hong, Y.; Lee, M.; Park, S.; Jin, Y.; Chang, K.-T.; Hong, Y. Beneficial effects of melatonin combined with exercise on endogenous neural stem/progenitor cells proliferation after spinal cord injury. *Int. J. Mol. Sci.* 2014, 15, 2207–2222. [CrossRef] [PubMed]
75. Wang, Z.; Liu, D.; Zhan, J.; Xie, K.; Wang, X.; Xian, X.; Gu, J.; Chen, W.; Hao, A. Melatonin improves short and long-term neurobehavioral deficits and attenuates hippocampal impairments after hypoxia in neonatal mice. *Pharmacol. Res.* 2013, 76, 84–97. [CrossRef] [PubMed]

76. Csernansky, J.G.; Martin, M.V.; Czeisler, B.; Meltzer, M.A.; Ali, Z.; Dong, H. Neuroprotective effects of olanzapine in a rat model of neurodevelopmental injury. *Pharmacol. Biochem. Behav.* 2006, 83, 208–213. [CrossRef]

77. Fu, J.; Zhao, S.-D.; Liu, H.-J.; Yuan, Q.-H.; Liu, S.-M.; Zhang, Y.-M.; Ling, E.-A.; Hao, A.-J. Melatonin promotes proliferation and differentiation of neural stem cells subjected to hypoxia in vitro. *J. Pineal Res.* 2011, 51, 104–112. [CrossRef]

78. Li, Z.; Li, X.; Bi, J.; Chan, M.T.V.; Wu, W.K.K.; Shen, J. Melatonin protected against the detrimental effects of microRNA-363 in a rat model of vitamin A-associated congenital spinal deformities. Involvement of Notch signaling. *J. Pineal Res.* 2019, 66, e12558. [CrossRef]

79. Guzman-Marin, R.; Suntsova, N.; Methippara, M.; Greiffenstein, R.; Szymbusiak, R.; McGinty, D. Sleep deprivation suppresses neurogenesis in the adult hippocampus of rats. *Eur. J. Neurosci.* 2005, 22, 2111–2116. [CrossRef]

80. Hairston, I.S.; Little, M.T.M.; Scanlon, M.D.; Barakat, M.T.; Palmer, T.D.; Sapolsky, R.M.; Heller, H.C. Sleep restriction suppresses neurogenesis induced by hippocampus-dependent learning. *J. Neurophysiol.* 2005, 94, 4224–4233. [CrossRef]

81. Hinojosa-Godinez, A.; Jave-Suarez, L.F.; Flores-Soto, M.; Gálvez-Conteras, A.Y.; Luquin, S.; Oregon-Romero, E.; González-Pérez, O.; González-Castañeda, R.E. Melatonin modifies SOX2+ cell proliferation in dentate gyrus and modulates SIRT1 and MECP2 in long-term sleep deprivation. *Neural Regen. Res.* 2019, 14, 1787–1795. [CrossRef]

82. López-Armas, G.; Flores-Soto, M.E.; Chaparro-Huerta, V.; Jave-Suarez, L.F.; Soto-Rodriguez, S.; Rusanova, I.; Acuña-Castroviejo, D.; González-Pérez, O.; González-Castañeda, R.E. Prophylactic Role of Oral Melatonin Administration on Neurogenesis in Adult Balb/C Mice during REM Sleep Deprivation. *Oxid. Med. Cell. Longev.* 2016, 2016, 2136902. [CrossRef] [PubMed]

83. Sompol, P.; Liu, X.; Baba, K.; Paul, K.N.; Tosini, G.; Iuvone, P.M.; Ye, K. N-acetylserotonin promotes hippocampal neuroprogenitor cell proliferation in sleep-deprived mice. *Proc. Natl. Acad. Sci. USA* 2011, 108, 8844–8849. [CrossRef]

84. Iggena, D.; Winter, Y.; Steiner, B. Melatonin restores hippocampal neural precursor cell proliferation and prevents cognitive deficits induced by jet lag simulation in adult mice. *J. Pineal Res.* 2017, 62, e12397. [CrossRef] [PubMed]

85. Reiter, R.J.; Tan, D.X.; Cabrera, J.; D’Arpa, D.; Sainz, R.M.; Mayo, J.C.; Ramos, S. The oxidant/antioxidant network: Role of melatonin. *Biol. Signals Recept* 1999, 8, 56–63. [CrossRef]

86. Tan, D.X.; Manchester, L.C.; Reiter, R.J.; Plummer, B.F.; Limson, J.; Weintraub, S.T.; Qi, W. Melatonin directly scavenges hydrogen peroxide: A potentially new metabolic pathway of melatonin biotransformation. *Free Radic. Biol. Med.* 2000, 29, 1177–1185. [CrossRef]

87. Aydogan, S.; Yerer, M.B.; Goktas, A. Melatonin and nitric oxide. *J. Endocrinol. Invest.* 2006, 29, 281–287. [CrossRef]

88. Cuzzocrea, S.; Zingarelli, B.; Gilad, E.; Hake, P.; Salzman, A.L.; Szabó, C. Protective effect of melatonin in carrageenan-induced models of local inflammation: Relationship to its inhibitory effect on nitric oxide production and its peroxynitrite scavenging activity. *J. Pineal Res.* 1997, 23, 106–116. [CrossRef]

89. Bilici, E.; Akpinar, E.; Kızıltunç, A. Protective effect of melatonin in carrageenan-induced acute local inflammation. *Pharmacol. Res.* 2002, 46, 133–139. [CrossRef]

90. Koh, P.-O. Melatonin regulates nitric oxide synthase expression in ischemic brain injury. *J. Vet. Med. Sci.* 2008, 70, 747–750. [CrossRef]

91. Song, J.; Kang, S.M.; Lee, K.M.; Lee, J.E. The protective effect of melatonin on neural stem cell against LPS-induced inflammation. *Biomed Res. Int.* 2015, 2015, 854359. [CrossRef]

92. Shu, T.; Fan, L.; Wu, T.; Liu, C.; He, L.; Pang, M.; Bu, Y.; Wang, X.; Wang, J.; Rong, L.; et al. Melatonin promotes neuroprotection of induced pluripotent stem cells-derived neural stem cells subjected to H2O2-induced injury in vitro. *Eur. J. Pharmacol.* 2018, 825, 143–150. [CrossRef] [PubMed]
93. Li, Z.; Li, X.; Chan, M.T.V.; Wu, W.K.K.; Tan, D.; Shen, J. Melatonin antagonizes interleukin-18-mediated inhibition on neural stem cell proliferation and differentiation. *J. Cell. Mol. Med.* 2017, 21, 2163–2171. [CrossRef] [PubMed]

94. Chen, B.H.; Ahn, J.H.; Park, J.H.; Choi, S.Y.; Lee, Y.L.; Kang, I.J.; Hwang, I.K.; Lee, T.K.; Shin, B.-N.; Lee, J.-C.; et al. Effects of scopolamine and melatonin cotreatment on cognition, neuronal damage, and neurogenesis in the mouse dentate gyrus. *Neurochem. Res.* 2018, 43, 600–608. [CrossRef] [PubMed]

95. Sirichoat, A.; Suwannakot, K.; Chaisawang, P.; Pannangrong, W.; Aranarochana, A.; Wigmore, P.; Welbat, J.U. Melatonin attenuates 5-fluorouracil-induced spatial memory and hippocampal neurogenesis impairment in adult rats. *Life Sci.* 2020, 248, 117468. [CrossRef] [PubMed]

96. Aranarochana, A.; Chaisawang, P.; Sirichoat, A.; Pannangrong, W.; Wigmore, P.; Welbat, J.U. Protective effects of melatonin against valproic acid-induced memory impairments and reductions in adult rat hippocampal neurogenesis. *Neuroscience* 2019, 406, 580–593. [CrossRef]

97. Sirichoat, A.; Krutsri, S.; Suwannakot, K.; Aranarochana, A.; Chaisawang, P.; Pannangrong, W.; Wigmore, P.; Welbat, J.U. Melatonin protects against methotrexate-induced memory deficit and hippocampal neurogenesis impairment in a rat model. *Biochem. Pharmacol.* 2019, 163, 225–233. [CrossRef]

98. Ruksee, N.; Tongjaroenbuangam, W.; Mahanam, T.; Govitrapong, P. Melatonin pretreatment prevented the effect of dexamethasone negative alterations on behavior and hippocampal neurogenesis in the mouse brain. *J. Steroid Biochem. Mol. Biol.* 2014, 143, 72–80. [CrossRef]

99. Rozisky, J.R.; Scarabelot, V.L.; de Oliveira, C.; Deitos, A.; Laste, G.; Caumo, W.; Torres, I.L.S. Melatonin as a potential counter-effect of hyperalgesia induced by neonatal morphine exposure. *Neurosci. Lett.* 2016, 633, 77–81. [CrossRef]

100. Choudhury, A.; Singh, S.; Palit, G.; Shukla, S.; Ganguly, S. Administration of N-acetylserotonin and melatonin alleviate chronic ketamine-induced behavioural phenotype accompanying BDNF-independent and dependent converging cytoprotective mechanisms in the hippocampus. *Behav. Brain Res.* 2016, 297, 204–212. [CrossRef]

101. Han, J.; Ji, C.; Guo, Y.; Yan, R.; Hong, T.; Dou, Y.; An, Y.; Tao, S.; Qin, F.; Nie, J.; et al. Mechanisms underlying melatonin-mediated prevention of fenvalerate-induced behavioral and oxidative toxicity in zebrafish. *J. Toxicol. Environ. Health Part A* 2017, 80, 1331–1341. [CrossRef]

102. Pipová Kokošová, N.; Kisková, T.; Vilhanová, K.; Štafuriková, A.; Jendželovský, R.; Račeková, E.; Šmajda, B. Melatonin mitigates hippocampal and cognitive impairments caused by prenatal irradiation. *Eur. J. Neurosci.* 2020. [CrossRef]

103. Naseri, S.; Moghabi, S.M.H.N.; Mokhtari, T.; Roghani, M.; Shirazi, A.R.; Malek, F.; Rastegar, T. Radio-Protective Effects of Melatonin on Subventricular Zone in Irradiated Rat: Decrease in Apoptosis and Upregulation of Nestin. *J. Mol. Neurosci.* 2017, 63, 198–205. [CrossRef] [PubMed]

104. Manda, K.; Ueno, M.; Anzai, K. Space radiation-induced inhibition of neurogenesis in the hippocampal dentate gyrus and memory impairment in mice: Ameliorative potential of the melatonin metabolite, AFMK. *J. Pineal Res.* 2008, 45, 430–438. [CrossRef] [PubMed]

105. Manda, K.; Ueno, M.; Anzai, K. Cranial irradiation-induced inhibition of neurogenesis in hippocampal dentate gyrus of adult mice: Attenuation by melatonin pretreatment. *J. Pineal Res.* 2009, 46, 71–78. [CrossRef] [PubMed]

106. Altun, G.; Kaplan, S.; Deniz, O.G.; Kocacan, S.E.; Canan, S.; Davis, D.; Marangoz, C. Protective effects of melatonin and omega-3 on the hippocampus and the cerebellum of adult Wistar albino rats exposed to electromagnetic fields. *J. Microsc. Ultrastruct.* 2017, 5, 230–241. [CrossRef] [PubMed]

107. Ekthuwapranee, K.; Sotthibundhu, A.; Tocharus, C.; Govitrapong, P. Melatonin ameliorates dexamethasone-induced inhibitory effects on the proliferation of cultured progenitor cells obtained from adult rat hippocampus. *J. Steroid Biochem. Mol. Biol.* 2015, 145, 38–48. [CrossRef]

108. Liu, C.; Zhou, W.; Li, Z.; Ren, J.; Li, X.; Li, S.; Liu, Q.; Song, F.; Hao, A.; Wang, F. Melatonin protects neural stem cells against tri-ortho-cresyl phosphate-induced autophagy. *Front. Mol. Neurosci.* 2020, 13, 25. [CrossRef]

109. Wongchitrat, P.; Lansubsakul, N.; Kamsrrijai, U.; Sae-Ung, K.; Mukda, S.; Govitrapong, P. Melatonin attenuates the high-fat diet and streptozotocin-induced reduction in rat hippocampal neurogenesis. *Neurochem. Int.* 2016, 100, 97–109. [CrossRef]
10. Li, H.; Zhang, Y.; Liu, S.; Li, F.; Wang, B.; Wang, J.; Cao, L.; Xia, T.; Yao, Q.; Chen, H.; et al. Melatonin enhances proliferation and modulates differentiation of neural stem cells via autophagy in hyperglycemia. *Stem Cells* **2019**, *37*, 504–515. [CrossRef]

11. Liu, S.; Guo, Y.; Yuan, Q.; Pan, Y.; Wang, L.; Liu, Q.; Wang, F.; Wang, J.; Hao, A. Melatonin prevents neural tube defects in the offspring of diabetic pregnancy. *J. Pineal Res.* **2015**, *59*, 508–517. [CrossRef]

12. Corrales, A.; Vidal, R.; García, S.; Vidal, V.; Martínez, P.; García, E.; Flórez, J.; Sanchez-Barceló, E.;J.; Martínez-Cué, C.; Rueda, N. Chronic melatonin treatment rescues electrophysiological and neuromorphological deficits in a mouse model of Down syndrome. *J. Pineal Res.* **2014**, *56*, 51–61. [CrossRef] [PubMed]

13. Corrales, A.; Parisotto, E.B.; Vidal, V.; García-Cerro, S.; Lantigua, S.; Diego, M.; Wilhem Filho, D.; Sanchez-Barceló, E.J.; Martínez-Cué, C.; Rueda, N. Pre- and post-natal melatonin administration partially regulates brain oxidative stress but does not improve cognitive or histological alterations in the T65Dn mouse model of Down syndrome. *Behav. Brain Res.* **2017**, *334*, 142–154. [CrossRef] [PubMed]

14. Uyanikgil, Y.; Turgut, M.; Ateš, U.; Baka, M.; Yurteseven, M.E. Beneficial effects of melatonin on morphological changes in postnatal cerebellar tissue owing to epileptiform activity during pregnancy in rats: Light and immunohistochemical study. *Brain Res. Dev. Brain Res.* **2005**, *159*, 79–86. [CrossRef]

15. Turgut, M.; Uyanikgil, Y.; Ateş, U.; Baka, M.; Yurteseven, M.E. Pinealectomy stimulates and exogenous melatonin inhibits harmful effects of epileptiform activity during pregnancy in the hippocampus of newborn rats: An immunohistochemical study. *Childs Nerv. Syst.* **2006**, *22*, 481–488. [CrossRef] [PubMed]

16. Cercós, M.G.; Galván-Arrieta, T.; Valdés-Tovar, M.; Solís-Chagoyán, H.; Argüeta, J.; Benítez-King, G.; Trueta, C. Abnormally increased secretion in olfactory neuronal precursors from a case of schizophrenia is modulated by melatonin: A pilot study. *Int. J. Mol. Sci.* **2017**, *18*, 1439. [CrossRef]

17. Liu, C.-H.; Chang, H.-M.; Yang, Y.-S.; Lin, Y.-T.; Ho, Y.-J.; Tseng, T.-J.; Lan, C.-T.; Li, S.-T.; Liao, W.-C. Melatonin promotes nerve regeneration following end-to-side neurorrhaphy by accelerating cytoskeletal remodeling via the melatonin receptor-dependent pathway. *Neuroscience* **2020**, *429*, 282–292. [CrossRef] [PubMed]

18. Chang, H.-M.; Liu, C.-H.; Hsu, W.-M.; Chen, L.-Y.; Wang, H.-P.; Wu, T.-H.; Chen, K.-Y.; Ho, W.-H.; Liao, W.-C. Proliferative effects of melatonin on Schwann cells: Implication for nerve regeneration following peripheral nerve injury. *J. Pineal Res.* **2014**, *56*, 322–332. [CrossRef]

19. Chang, H.M.; Ling, E.A.; Lue, J.H.; Wen, C.Y.; Shieh, J.Y. Melatonin attenuates neuronal NADPH-d/NOS expression in the hypoglossal nucleus of adult rats following peripheral nerve injury. *Brain Res.* **2000**, *873*, 243–251. [CrossRef]

20. Chang, H.-M.; Huang, Y.-L.; Lan, C.-T.; Wu, U.-I.; Hu, M.-E.; Yoon, S.-C. Melatonin preserves superoxide dismutase activity in hypoglossal motoneurons of adult rats following peripheral nerve injury. *J. Pineal Res.* **2008**, *44*, 172–180. [CrossRef]

21. Borsans, E.; Buffoli, B.; Bonazza, V.; Reiter, R.J.; Rezzani, R.; Rodella, L.F. Single Administration of Melatonin Modulates the Nitroxidergic System at the Peripheral Level and Reduces Thermal Nociceptive Hypersensitivity in Neuropathic Rats. *Int. J. Mol. Sci.* **2017**, *18*, 2143. [CrossRef]

22. Areti, A.; Komirishetty, P.; Akuthota, M.; Malik, R.A.; Kumar, A. Melatonin prevents mitochondrial dysfunction and promotes neuroprotection by inducing autophagy during oxaliplatin-evoked peripheral neuropathy. *J. Pineal Res.* **2017**, *62*, e12393. [CrossRef] [PubMed]

23. Sayan, H.; Ozacmak, V.H.; Ozen, O.A.; Coskun, O.; Arslan, S.O.; Sezen, S.C.; Aktas, R.G. Beneficial effects of melatonin on reperfusion injury in rat sciatic nerve. *J. Pineal Res.* **2004**, *37*, 143–148. [CrossRef] [PubMed]

24. Kaya, Y.; Sankcuğlu, L.; Aslan, M.; Kencebay, C.; Demir, N.; Derin, N.; Angelov, D.N.; Yıldırım, F.B. Comparison of the beneficial effect of melatonin on recovery after cut and crush sciatic nerve injury: A combined study using functional, electrophysiological, biochemical, and electron microscopic analyses. *Childs Nerv. Syst.* **2013**, *29*, 389–401. [CrossRef] [PubMed]

25. Turgut, M.; Uysal, A.; Pehlivam, M.; Öktem, G.; Yurteseven, M.E. Assessment of effects of pinealectomy and exogenous melatonin administration on rat sciatic nerve suture repair: An electrophysiological, electron microscopic, and immunohistochemical study. *Acta Neurochir.* **2005**, *147*, 67–77. [CrossRef] [PubMed]